Autosomal Recessive Nonsyndromic Hearing Loss 77

Mendelian MONDO:0013119 Pathograph 12 Show in embeddings browser Nonsyndromic Hearing Loss

DFNB77 is autosomal recessive nonsyndromic hearing loss caused by biallelic variants in LOXHD1, a protein built almost entirely of PLAT (polycystin/lipoxygenase/alpha-toxin) repeats and distributed along the length of the hair-cell stereociliary membrane. It was identified by going the unusual direction - from a mouse mutant to a human family. The ENU-induced *samba* line was mapped to Loxhd1, and the human gene was then screened in deafness families, which is how DFNB77 was found. The mechanism is the interesting part, and it is specific enough to be worth stating precisely rather than as "hair cells degenerate". Stereociliary development is normal in mutant mice. The hair bundle is morphologically intact, tip links are present in normal numbers, and the upper and lower tip-link complex proteins Harmonin and LHFPL5 are still correctly localised. What fails is the mechanotransduction current itself, and only after a delay: mechanotransduction in mutant inner hair cells is at wild-type levels through the first postnatal week and severely affected by postnatal day 11, tracking the timing of LOXHD1's own arrival in the bundle. The machinery is present but not activatable. Hair cells then degenerate secondarily. That sequence - normal development, then transduction failure, then degeneration - is what makes DFNB77 a *progressive* hearing loss rather than a congenital-profound one, and it puts the disease in a small class. The founding report names LOXHD1, MYO3A and PJVK as the only human genes then linked to progressive autosomal recessive nonsyndromic hearing loss, and proposes age-dependent hair-cell failure as their common mechanism. Two further things are curated here because they are the sort of detail that gets flattened. LOXHD1 variants have been reported in auditory neuropathy spectrum disorder, with preserved cochlear microphonic and partial otoacoustic emissions - a presentation a curator expecting "sensorineural hearing loss" would not predict. And LOXHD1 is a recurring, non-trivial contributor to diagnostic yield in unselected hearing-loss cohorts, not a one-family curiosity. Two cohort studies since 2018 have also settled things that would otherwise be left as plausible inference, and both settled them negatively. Vestibular function is spared: a nine-family Dutch series found no evidence of vestibular involvement, and a screen of 8,074 Japanese hearing-loss patients found no accompanying symptoms including vestibular dysfunction. That matters because LOXHD1 is expressed in vestibular as well as cochlear hair cells, so sparing is a finding rather than an absence of interest. And there is no genotype-phenotype correlation to be had: the Dutch series looked for one across fifteen variants and could not establish it, attributing the inter- and intrafamilial variation to modifiers or environment instead.

Ask OpenScientist

Ask a research question about Autosomal Recessive Nonsyndromic Hearing Loss 77. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
5
Pathophys.
3
Phenotypes
2
Gaps
12
Pathograph
1
Genes
2
Variants
3
Medical Actions
2
Models
1
Deep Research
👪

Inheritance

1
Autosomal recessive HP:0000007
Biallelic LOXHD1 variants. Reported as homozygous in consanguineous families and as compound heterozygous elsewhere.
Autosomal recessive inheritance
Show evidence (2 references)
PMID:19732867 SUPPORT Human Clinical
"we screened DNA from human families segregating deafness and identified a mutation in LOXHD1, which causes DFNB77, a progressive form of autosomal-recessive nonsyndromic hearing loss (ARNSHL)"
Establishes the recessive inheritance and names the locus.
PMID:36472766 SUPPORT Human Clinical
"This study identified biallelic mutations as the underlying cause of early onset DFNB in six Pakistani families."
Independent confirmation of biallelic inheritance for LOXHD1 among the DFNB genes in this cohort.
?

Discussions and Knowledge Gaps

2
Severity and rate of progression in DFNB77 vary widely within families carrying the same variants. If the LOXHD1 genotype does not predict them, what does?
KNOWLEDGE GAP OPEN dfnb77_no_genotype_phenotype_correlation
Attached to
genetic#LOXHD1 phenotypes#Progressive Sensorineural Hearing Impairment progression#Onset
Two independent groups looked for a genotype-phenotype correlation and neither found one. Established: the hearing phenotype varies in severity and progression both between and within families; fifteen pathogenic variants across nine Dutch families gave no relationship between variant type or position and severity or progression; a Japanese cohort of 28 individuals, 18 of them sharing one recurrent splice variant, likewise showed different progression rates. The intrafamilial part is the sharp end - siblings with identical genotypes diverge, so ancestry and allele are both controlled and the variation survives. Not established: the cause. Both groups reach for the same pair of candidates and neither tests them - the Dutch series hypothesises environmental factors or genetic modifiers, and the Japanese cohort speculates the same. No modifier locus has been proposed, and no environmental exposure has been examined. Noise exposure is the obvious candidate for a disease of progressive hair-cell degeneration and, as far as the sources cited here go, nobody has asked. This matters for counselling more than for mechanism. A family given a molecular diagnosis wants to know how bad it will get, and the honest answer is that the genotype does not say.
Proposed experiments
Modifier and noise-exposure study in the Japanese c.4212+1G>A cohort
exp_dfnb77_modifier_and_exposure_study
The 18 individuals homozygous or compound heterozygous for the same recurrent splice variant are an unusually clean natural experiment: allele held constant, ancestry largely held constant, phenotype varying. Genotype them for known hearing-loss modifier loci and collect lifetime noise-exposure and ototoxic-drug history, then test both against audiometric slope.
Would support
genetic#LOXHD1
Supporting outcome
  • Progression rate tracks a modifier locus or a measured exposure, converting an unexplained variance into a counselling-relevant and potentially modifiable factor.
Refuting outcome
  • Neither modifiers nor exposure explain the variance in a cohort sharing one allele, indicating the variability is stochastic at the level of hair-cell survival and that no prognostic statement is available at diagnosis.
Show evidence (2 references)
PMID:29676012 SUPPORT Human Clinical
"a clear correlation between the type or location of the variant and the severity or progression of HI could not be established. We hypothesize that environmental factors or genetic modifiers are responsible for phenotypic differences."
The negative result and the authors' own untested explanation for it, quoted together because the hypothesis is doing no work until somebody tests it.
PMID:31547530 SUPPORT Human Clinical
"Patients with LOXHD1 variations mostly showed early onset hearing loss and presented different progression rates. We speculated that the varying severities and progression rates of hearing loss are the result of environmental and/or other genetic factors."
Independent replication of both the observation and the untested explanation, in a much larger cohort dominated by a single shared allele.
The mechanotransduction machinery is present and correctly localised in LOXHD1-mutant hair cells but does not conduct. What does LOXHD1 do that the assembled machinery needs?
KNOWLEDGE GAP OPEN dfnb77_how_loxhd1_gates_transduction
Attached to
pathophysiology#LOXHD1 Loss of Function in Stereocilia pathophysiology#Hair-Cell Mechanotransduction Failure with Intact Bundle Architecture
This is a well-posed gap rather than a general absence of knowledge, because the obvious answers have been tested and excluded. Established: LOXHD1 is fifteen PLAT repeats distributed along the stereociliary membrane; it arrives late in postnatal bundle development; mechanotransduction currents are normal in the first postnatal week and severely reduced by day 11, tracking that arrival; the hair bundle is morphologically normal; tip-link number is not reduced; Harmonin and LHFPL5 are correctly localised. Excluded by those measurements: a developmental bundle malformation, a tip-link deficiency, and a failure to assemble the tip-link protein complexes. Not established: the actual function. The generic positional evidence is weak - PLAT repeats bind lipids and proteins *in other proteins*, an inference from domain class rather than a demonstrated activity of LOXHD1, and the mechanism paper says so in those words. There is, however, one piece of LOXHD1-specific evidence pointing the same way, and it should be named rather than glossed as "untested": molecular modelling of the p.V1892F mutant predicts a distorted PLAT domain with decreased affinity for the lipid membrane, which would cause hair-cell dysfunction. That is a computational prediction on a single variant, not a measurement, so the membrane-lipid-organising hypothesis has a specific form and no experimental test - which is a different and more tractable state than having no hypothesis at all. A role in delivering or retaining a component not assayed in the mechanism study remains a competing candidate with nothing behind it either way. The clinical reason this matters: if LOXHD1 maintains an activatable state rather than building the machinery, the machinery is intact in a patient's hair cells until they degenerate - which would define a window in which a small-molecule or gene-replacement approach has something left to act on. If instead LOXHD1 is needed to build something not yet measured, that window is narrower or absent.
Proposed experiments
What LOXHD1 binds at the stereociliary membrane
exp_dfnb77_loxhd1_interactome_and_lipid_binding
Determine the lipid- and protein-binding partners of the LOXHD1 PLAT repeats at the stereociliary membrane - by proximity labelling in hair cells and by direct lipid-binding assays on the tenth repeat, the one both mouse alleles disrupt - and test whether the identified partners are mislocalised or lost in mutant bundles at postnatal day 11.
Would support
pathophysiology#Hair-Cell Mechanotransduction Failure with Intact Bundle Architecture
Supporting outcome
  • LOXHD1 is shown to organise a specific membrane lipid environment or retain a specific partner at the transduction site, and that environment or partner is disrupted in mutants - naming the LOXHD1-dependent step and identifying a target.
Refuting outcome
  • No consistent binding partner or lipid dependency is found and mutant bundles are indistinguishable from wild type on every measured axis, indicating the defect lies somewhere the current assays do not reach and that the mechanism curated here stops one step short of the lesion.
Show evidence (3 references)
PMID:33707295 SUPPORT Model Organism
"suggesting that the mechanotransduction machinery was present but not activatable"
The statement of the gap - what is left unexplained once the alternatives are excluded.
PMID:33707295 SUPPORT Model Organism
"This work identified a novel LOXHD1-dependent step in hair bundle development that is critical for mechanotransduction in mature hair cells as well as for normal hearing function in mice and humans."
The authors name the missing step as novel and LOXHD1-dependent without characterising it, which is precisely the shape of this gap.
PMID:26973026 SUPPORT Computational
"Molecular modeling predicted that distorted structure of the PLAT domain in the p.V1892F mutant could lead to decreased affinity of the protein to lipid membrane resulting in hair cell dysfunction."
The one LOXHD1-specific prediction of a lipid-binding role, which is why this gap is described as lacking an experimental test rather than lacking a hypothesis. Graded COMPUTATIONAL, and the authors' hedge "could lead to" is kept in the quote.
⚙

Pathophysiology

5
LOXHD1 Loss of Function in Stereocilia
Biallelic LOXHD1 variants remove or disable a protein consisting entirely of PLAT (polycystin/lipoxygenase/alpha-toxin) repeats - fifteen of them - which in other proteins bind lipids and proteins. LOXHD1 is distributed along the length of the stereocilia rather than concentrated at the tip-link ends, and it is evolutionarily conserved. Its arrival in the hair bundle is late. Both published mouse models carry mutations in the tenth PLAT repeat, and the functional consequence appears only as postnatal LOXHD1 expression and localisation in the bundle reach their normal level - which is what makes this a maintenance protein rather than a developmental one.
cochlear inner hair cell CL:0000589 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cochlear inner hair cell (CL:0000589). CL:0000589 is a cell type from the Cell Ontology.
LOXHD1 hgnc:26521 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves LOXHD1 (hgnc:26521). hgnc:26521 is a gene from the HUGO Gene Nomenclature Committee.
Genetic context allele_type: VARIANT variant_origin: GERMLINE zygosity: HOMOZYGOUS functional_impact_category: LOSS_OF_FUNCTION
hair-cell stereocilium membrane GO:0032420 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves hair-cell stereocilium membrane, annotated with stereocilium (GO:0032420). GO:0032420 is a cellular component from the Gene Ontology.
Downstream
Hair-Cell Mechanotransduction Failure with Intact Bundle Architecture
Show evidence (2 references)
PMID:19732867 SUPPORT Model Organism
"LOXHD1 consists entirely of PLAT (polycystin/lipoxygenase/alpha-toxin) domains and is expressed along the membrane of mature hair cell stereocilia."
The protein's composition and its subcellular location, which together define this node.
PMID:33707295 SUPPORT INDIRECT Model Organism
"LOXHD1 consists of 15 polycystin lipoxygenase α-toxin (PLAT) repeats, which in other proteins can bind lipids and proteins."
The repeat count and the functional class of the repeats. INDIRECT because the inference that LOXHD1's repeats bind lipids and proteins is carried over from other PLAT-domain proteins rather than demonstrated for LOXHD1 - the authors' own hedge "in other proteins" is kept in the quote.
Hair-Cell Mechanotransduction Failure with Intact Bundle Architecture
The central mechanistic finding, and it is defined as much by what is normal as by what is not. Mutant inner hair cells have mechanotransduction currents at wild-type levels through the first postnatal week and severely reduced currents by postnatal day 11. Over the same interval the hair bundle stays morphologically normal, tip-link number is not reduced, and Harmonin and LHFPL5 - proteins of the upper and lower tip-link complexes - remain correctly localised. The authors' reading is that the transduction machinery is present but not activatable. That is a specific claim and it excludes the two obvious alternatives, which is why this entry states the exclusions rather than only the positive finding: this is not a bundle malformation and it is not a tip-link deficiency.
cochlear inner hair cell CL:0000589 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cochlear inner hair cell (CL:0000589). CL:0000589 is a cell type from the Cell Ontology.
mechanotransduction in cochlear hair cells GO:0050910 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased mechanotransduction in cochlear hair cells, annotated with detection of mechanical stimulus involved in sensory perception of sound (GO:0050910). GO:0050910 is a biological process from the Gene Ontology. ↓ DECREASED
stereocilium bundle GO:0032421 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves stereocilium bundle (GO:0032421). GO:0032421 is a cellular component from the Gene Ontology.
Animal models
Loxhd1 mouse models with tenth PLAT-repeat mutations Mouse measures Direct electrophysiological measurement of the failing step, with the structural alternatives measured in the same animals and found normal.
Downstream
Progressive Hair-Cell Degeneration
Show evidence (3 references)
PMID:33707295 SUPPORT INDIRECT Model Organism
"While mechanotransduction currents in mutant inner hair cells (IHCs) were similar to wild-type levels in the first postnatal week, they were severely affected by postnatal day 11."
The measurement itself, with its timing. INDIRECT for the human disease because the recordings are murine; the timing is what links it to the progressive human course.
PMID:33707295 SUPPORT INDIRECT Model Organism
"The mechanotransduction defect observed in Loxhd1-mutant IHCs was not accompanied by a morphologic defect of the hair bundle or a reduction in TL number."
The exclusion that makes this node specific: not a bundle malformation and not a tip-link deficiency. Recorded as SUPPORT because it supports this node's claim by ruling out the alternatives, and INDIRECT because that is an inference from a negative result.
PMID:33707295 SUPPORT INDIRECT Model Organism
"we found that two proteins of the upper and lower TL protein complexes (Harmonin and LHFPL5) were maintained in the mutants, suggesting that the mechanotransduction machinery was present but not activatable"
The strongest statement of this node's claim, with the authors' hedge "suggesting" kept in the quote. INDIRECT for the same reason as above.
Progressive Hair-Cell Degeneration
Hair cells that develop normally and then fail to transduce do not survive. In samba mice, stereociliary development is unaffected, hair-cell function is perturbed, and hair cells eventually degenerate. The ordering matters clinically: it is what makes the human hearing loss progressive rather than congenital and stable, and it is what defines the therapeutic window, if one ever exists, as the interval before degeneration.
auditory hair cell CL:0000202 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves auditory hair cell (CL:0000202). CL:0000202 is a cell type from the Cell Ontology.
Animal models
samba mouse (ENU-induced Loxhd1 mutant) Mouse recapitulates Reproduces the human sequence: normal stereociliary development, then perturbed hair-cell function, then hair-cell degeneration - matching the progressive rather than congenital character of the human hearing loss.
Downstream
Progressive Sensorineural Hearing Loss
Show evidence (1 reference)
PMID:19732867 SUPPORT INDIRECT Model Organism
"Stereociliary development is unaffected in samba mice, but hair cell function is perturbed and hair cells eventually degenerate."
States the whole sequence in one sentence - normal development, functional failure, then degeneration. INDIRECT for the human disease because the histology is murine.
Vestibular Hair-Cell Sparing
Vestibular hair cells are spared, and there is a mechanistic reason rather than a coincidence. LOXHD1 is expressed in the hair cells of the vestibule as well as the cochlea, so the null expectation is vestibular involvement - but vestibular hair cells express only reduced amounts of LOXHD1 and are not affected by the mutation in samba mice. The dose difference is what makes the disease non-syndromic. The clinical correlate is replicated across every series that looked: normal and symmetrical vestibular evoked myogenic potentials in a reported proband, no vestibular involvement in a nine-family Dutch series, and no accompanying symptoms including vestibular dysfunction in a screen of 8,074 Japanese hearing-loss patients. This is modelled as a pathophysiology node rather than as a phenotype because the schema has no way to record a phenotype as explicitly absent - `FrequencyEnum` has no EXCLUDED value (HP:0040285) and `Phenotype` has no negation slot. An earlier revision of this entry did record it as a phenotype bound to `HP:0001751` "Abnormal vestibular function", which is the opposite of the finding and would have exported as a claim that DFNB77 causes vestibular dysfunction. That was wrong and is the reason the rule "no term beats a bad one" exists. See issue #10190. Following the pattern of "Preserved Zona Glomerulosa Mineralocorticoid Production" in `kb/disorders/Familial_Glucocorticoid_Deficiency.yaml`. This node is deliberately isolated - nothing points to it and it points nowhere. That is what a sparing claim is: the LOXHD1 lesion does not cause the sparing, it fails to reach the tissue, so an incoming `downstream` edge would assert a causal relation that runs the wrong way. The node exists to record that the vestibular arm was looked at and found intact, which is what makes the disease non-syndromic.
vestibular hair cell CL:0000609 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves vestibular hair cell (CL:0000609). CL:0000609 is a cell type from the Cell Ontology.
Show evidence (4 references)
PMID:35875410 SUPPORT INDIRECT Model Organism
"vestibular hair cells only expressed reduced amounts of LOXHD1 and are not affected by the mutation in the samba mice, which corroborate the lack of vestibular and balance issues in the developing siblings and presence of normal VEMP in the proband"
The mechanistic explanation and the clinical corroboration in one sentence. Graded MODEL_ORGANISM because the expression-level claim it rests on is murine, and INDIRECT because this paper is reporting Grillet's result rather than measuring it. The quote is cut before the sentence's inline numeric citation markers, which the reference validator strips from the query but not from the cached text.
PMID:35875410 SUPPORT Human Clinical
"Clinical reports of LOXHD1 mutations have not revealed any vestibular symptoms in affected individuals."
The literature-wide clinical statement, which is what makes the sparing a general property of the disease rather than an observation in one series.
PMID:29676012 SUPPORT Human Clinical
"There was no evidence for involvement of the vestibular system."
The human negative, from a series assembled specifically to characterise the audiovestibular phenotype - so it comes from a study designed to find involvement if it were there.
+ 1 more reference
Progressive Sensorineural Hearing Loss
The clinical endpoint. Hearing loss that is progressive rather than static, which the founding report places in a class of three genes - LOXHD1, MYO3A and PJVK - all of which are required for hair-cell function rather than for hair-cell development, and for which it proposes age-dependent hair-cell failure as the shared mechanism.
Downstream
Progressive Sensorineural Hearing Impairment
Show evidence (1 reference)
PMID:19732867 SUPPORT Human Clinical
"LOXHD1, MYO3a, and PJVK are the only human genes to date linked to progressive ARNSHL. These three genes are required for hair cell function, suggesting that age-dependent hair cell failure is a common mechanism for progressive ARNSHL."
The clinical class this disease belongs to and the mechanism the authors propose for it, with their hedge "suggesting" preserved.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Autosomal Recessive Nonsyndromic Hearing Loss 77 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

3
Progressive Sensorineural Hearing Impairment VERY_FREQUENT Auditory HP:0000408 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Progressive sensorineural hearing impairment (HP:0000408), qualified as course progressive. HP:0000408 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:19732867 SUPPORT Human Clinical
"we screened DNA from human families segregating deafness and identified a mutation in LOXHD1, which causes DFNB77, a progressive form of autosomal-recessive nonsyndromic hearing loss (ARNSHL)"
Names the phenotype and its progressive character in the founding human family.
Prelingual Onset Hearing Loss FREQUENT Auditory HP:0000399 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Prelingual sensorineural hearing impairment (HP:0000399), qualified as congenital onset. HP:0000399 is a phenotype from the Human Phenotype Ontology.
Onset: CONGENITAL
Show evidence (3 references)
PMID:36472766 SUPPORT Human Clinical
"We identified eight pathogenic or likely pathogenic mutations in LOXHD1, GJB2, SLC26A4, MYO15A, and TMC1 from six families."
Places LOXHD1 among the genes solving prelingual-onset DFNB in this cohort, which is the basis for recording an early-onset presentation.
PMID:31547530 SUPPORT Human Clinical
"Patients with LOXHD1 variations mostly showed early onset hearing loss and presented different progression rates."
The frequency-bearing statement behind the FREQUENT band - "mostly" in a 28-patient cohort. Note that the same sentence records variable progression, which is why onset is banded but rate of progression is not.
PMID:34753855 REFUTE Human Clinical
"Four autosomal-recessive genes demonstrated an association with late hearing loss onset in single cases (TMPRSS3, GJB2, LOXHD1, and SLC26A4)."
Refutes prelingual onset as an obligate feature: in an age-balanced cohort LOXHD1 also turned up among the late-onset diagnoses. Recorded against this phenotype rather than omitted, so a reader does not take early onset as a rule-out for late presentation.
Auditory Neuropathy Spectrum Disorder Presentation VERY_RARE Auditory HP:0006958 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Auditory Neuropathy Pattern, annotated with Abnormal auditory evoked potentials (HP:0006958). HP:0006958 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:35875410 SUPPORT Human Clinical
"All three subjects had evidence of some, albeit few, functioning cochlear hair cells as revealed by the presence of a cochlear microphonic and/or partial otoacoustic emissions early in life."
The audiological finding that defines this presentation, and the one that shows residual hair-cell function. Bound to Abnormal auditory evoked potentials rather than to the generic sensorineural-hearing-impairment term, because the abnormal-ABR-with-preserved-OAE signature is what distinguishes ANSD from the entry's main phenotype rather than restating it - the same binding used for "Auditory Neuropathy Pattern" in `kb/disorders/Perrault_Syndrome.yaml`.
PMID:35875410 SUPPORT Human Clinical
"To our knowledge, this is the first association between LOXHD1 mutations and ANSD in two patients who have been successfully managed with cochlear implants."
Establishes the association as novel at the time of reporting and records the management outcome, which is why this presentation matters clinically rather than only descriptively.
🧬

Genetic Associations

1
LOXHD1
Gene: LOXHD1 hgnc:26521 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is LOXHD1 (hgnc:26521). hgnc:26521 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (2 references)
PMID:19732867 SUPPORT Human Clinical
"Based on the studies in mice, we screened DNA from human families segregating deafness and identified a mutation in LOXHD1, which causes DFNB77"
The gene-disease relationship and, in the same sentence, the mouse-first route by which it was established.
PMID:34753855 SUPPORT Human Clinical
"At the single-gene level, causative variants in GJB2 were the most common cause among autosomal-recessive genes (45%), followed by MYO15A and SLC26A4 (both 10%), TMPRSS3 and LOXHD1 (both 7%)."
Quantifies LOXHD1's share among autosomal recessive diagnoses in an unselected cohort, which is what establishes it as a routine contributor rather than a single-family gene.
Variants (2)
c.4212+1G>A
Recurrent splice-donor variant found in 18 of 28 LOXHD1-positive individuals in a Japanese hearing-loss cohort and reported only in Japanese patients. Haplotype analysis indicates a mutational hot spot arising in multiple ancestors rather than a single founder event.
Show evidence (1 reference)
PMID:31547530 SUPPORT Human Clinical
"A recurrent variant c.4212 + 1G > A, only reported in Japanese patients, was detected in 18 individuals. Haplotype analysis implied that this variation occurred in a mutational hot spot, and that multiple ancestors of Japanese population had this variation."
The allele, its frequency in that cohort, its population restriction, and the haplotype result that distinguishes a hot spot from a founder effect.
p.D278Y and p.D1219E compound heterozygous pair
Novel compound heterozygous LOXHD1 alleles reported in a Pakistani family with prelingual autosomal recessive nonsyndromic hearing loss. Both are missense changes at conserved residues.
Show evidence (1 reference)
PMID:36472766 SUPPORT Human Clinical
"The four missense or start-loss mutations were located at well conserved residues, and most in silico analysis predicted their pathogenicity."
Supports the conservation and predicted pathogenicity of the missense alleles reported in that cohort. The allele designations themselves are given in square-bracketed notation in the source sentence, which the reference validator strips, so they are carried in this variant's name and description instead.
💊

Medical Actions

3
Hearing Aid Amplification
Action: hearing aid amplificationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is hearing aid amplification, annotated with Rehabilitation (NCIT:C15315), qualified as medical device hearing aid. NCIT:C15315 is a clinical intervention from the NCI Thesaurus. Ontology label: Rehabilitation NCIT:C15315
First-line intervention and, for a disease whose reported severity runs from mild to profound, the one most patients receive. In the reported LOXHD1 auditory-neuropathy family all three children were fitted early - at 9 months, at 7 weeks, and at 6 months - and the outcomes diverged in a way worth recording: the cousin's aided thresholds were in the mild range at three and a half years, while the two sisters showed discomfort with amplification and limited aided response and went on to implantation. That divergence is the practical content of this entry's progression section. Amplification is the right starting point, and progression means it may stop being sufficient, so aided testing has to be repeated rather than treated as a settled result.
Mechanism Target:
Progressive Sensorineural Hearing Loss — Compensates for the threshold loss. It does not act on the transduction defect or slow the hair-cell degeneration driving it.
Show evidence (2 references)
PMID:35875410 SUPPORT Human Clinical
"The cousin proband was fitted with hearing aids at 6 months of age."
The one reported case where amplification alone gave a good aided outcome - his aided pure tone thresholds at three and a half years were in the mild range with an aided SRT of 25 dB. That clause is not quoted because the source renders the age with a fraction character the reference validator cannot match.
PMID:35875410 REFUTE Human Clinical
"She was bilaterally fitted with loaner hearing aids at 9 months. She quickly displayed signs of discomfort with louder sounds and the overall gain and output limit were subsequently decreased for both hearing aids."
Refutes amplification as sufficient in the severe end of the reported spectrum. Recorded against this treatment rather than omitted, because both outcomes came from the same three-child family and presenting only the good one would misrepresent it.
Cochlear Implantation
Action: cochlear device implantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is cochlear device implantation, annotated with Surgical Procedure (NCIT:C15329), qualified as medical device cochlear implant. NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Two of the three reported LOXHD1 auditory-neuropathy children were successfully managed with cochlear implants. This is a reasonable expectation on mechanism as well as on report: the lesion is at the hair-cell transduction step, upstream of the spiral ganglion and auditory nerve, so direct electrical stimulation bypasses it. Note the treatment term binds the clinical action, not the device. `NCIT:C157820` "Cochlear Implant" names the equipment and has no `NCIT:C25218` ancestor, so it cannot sit in a `TreatmentTerm`; it is attached as a qualifier instead, which keeps the device concept queryable.
Mechanism Target:
Hair-Cell Mechanotransduction Failure with Intact Bundle Architecture — Bypasses the failed step rather than correcting it. The implant stimulates the auditory nerve directly, so it does not depend on hair-cell transduction. One caveat on that reasoning, which the outcomes so far do not resolve: the samba mouse shows some spiral ganglion neuron loss, thought to be secondary to hair-cell damage rather than a primary LOXHD1 effect. If that holds in humans, the target the implant stimulates is itself degenerating slowly, and long-term outcome could depend on implanting before it does. The reported patients argue against this mattering much in practice - one is a normal-audiogram, 100%-word-score implant user eight years on - but two patients is not a basis for a claim about implant timing.
Show evidence (3 references)
PMID:35875410 SUPPORT Human Clinical
"To our knowledge, this is the first association between LOXHD1 mutations and ANSD in two patients who have been successfully managed with cochlear implants."
The reported outcome. Two patients is a small basis, and the entry does not present this as an established outcome rate for DFNB77 - only that implantation succeeded where it was tried and reported.
PMID:35875410 SUPPORT INDIRECT Human Clinical
"presented 2 patients with severe-profound bilateral sensorineural hearing loss due to LOXHD1 mutations who also benefited from cochlear implants."
An independent group's implant outcome in LOXHD1 patients, which takes the basis beyond one family. INDIRECT because it reaches this entry as a citation inside the paper being quoted rather than from the original report.
PMID:35875410 SUPPORT INDIRECT Model Organism
"observed in his study some spiral ganglion neuron loss, thought to be a secondary consequence of hair cell damage"
The caveat on the "the lesion is upstream of the spiral ganglion" reasoning. Graded MODEL_ORGANISM because the observation is in samba mice, and INDIRECT because this paper reports it from Grillet rather than measuring it.
Genetic Counseling
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Autosomal recessive with a 25% recurrence risk. Counselling for DFNB77 has to carry the progression: unlike most autosomal recessive nonsyndromic hearing loss, this one worsens, so a child's initial audiogram is not their final one and follow-up audiometry is part of the plan rather than an optional extra.
Show evidence (1 reference)
PMID:19732867 SUPPORT Human Clinical
"LOXHD1, MYO3a, and PJVK are the only human genes to date linked to progressive ARNSHL."
The progression that counselling has to convey, and the reason DFNB77 is counselled differently from a static recessive hearing loss.
🔬

Diagnosis

2
Hearing Loss Gene Panel or Exome Sequencing
DFNB77 is nonsyndromic, so there is no clinical feature that points at LOXHD1 specifically; diagnosis is by sequencing. LOXHD1 is on contemporary hearing-loss panels and is a routine contributor to yield, so panel testing rather than exome is usually sufficient. Yield in an unselected cohort is strongly phenotype-dependent, which is worth knowing before ordering: early onset with a recessive family history and higher-grade loss reached 60%, while late onset and lower-grade loss yielded significantly fewer diagnoses.
Show evidence (2 references)
PMID:34753855 SUPPORT Human Clinical
"A positive family history of autosomal-recessive inheritance in combination with early onset and higher grades of hearing loss significantly increased the solve rate up to 60%, while late onset and lower grades of hearing loss yielded significantly fewer diagnoses."
The phenotype-dependence of diagnostic yield, which is the practical guidance a clinician needs before testing.
PMID:34753855 SUPPORT Human Clinical
"Targeted hearing loss gene panel analysis proved to be an effective tool for ensuring an appropriate diagnostic yield in a routine clinical setting including the identification of novel variants and medically significant reclassifications."
Supports panel sequencing as the routine diagnostic modality for this class of disease.
Audiological Testing Including Otoacoustic Emissions and Cochlear Microphonic
Standard audiometry plus otoacoustic emissions, auditory brainstem responses and cochlear microphonic. The reason to specify the full battery rather than audiometry alone is the auditory-neuropathy presentation: in the reported LOXHD1 ANSD children, a cochlear microphonic and partial otoacoustic emissions were present early in life, which is the finding that identifies ANSD and changes management. An audiogram alone would not have shown it.
Show evidence (1 reference)
PMID:35875410 SUPPORT Human Clinical
"They were assessed with a standard clinical test battery including distortion otoacoustic emissions, auditory brainstem responses and audiometry."
The test battery used, and the one that made the ANSD presentation visible.
📈

Progression

2
Onset
Age: prelingual to late onset
Onset is not consistent across reports and the entry does not pick one. Pakistani families with LOXHD1 among the solved genes had prelingual onset; the age-balanced German cohort found LOXHD1 among genes associated with late hearing-loss onset in single cases. The mouse data give a mechanistic reason to expect variability rather than a fixed onset: the defect appears when LOXHD1 reaches its normal level in the bundle, so anything that shifts residual protein function shifts the timing.
Show evidence (1 reference)
PMID:34753855 SUPPORT Human Clinical
"Four autosomal-recessive genes demonstrated an association with late hearing loss onset in single cases (TMPRSS3, GJB2, LOXHD1, and SLC26A4)."
The late-onset end of the reported range.
Established disease
Progressive. The founding report classifies DFNB77 as one of the few progressive forms of autosomal recessive nonsyndromic hearing loss, and the mouse mechanism supplies the reason: hair cells fail functionally and then degenerate, so hearing worsens with age rather than being fixed at its initial level. No longitudinal audiometric series for DFNB77 patients has been published, so the rate of progression is not characterised.
Show evidence (1 reference)
PMID:19732867 SUPPORT Human Clinical
"LOXHD1, MYO3a, and PJVK are the only human genes to date linked to progressive ARNSHL."
Places DFNB77 in the progressive class of ARNSHL.
📊

Prevalence

2
Japanese hearing-loss patients screened by massively parallel sequencing
Unknown Unknown
The best denominator published for this disease: 28 affected individuals carrying 21 LOXHD1 variants, from a screen of 8,074 Japanese hearing-loss patients. That is roughly 0.35% of an ascertained hearing-loss cohort, not a population prevalence, and it is not transferable to other ancestries - 18 of the 28 carry one recurrent splice variant seen only in Japanese patients. `measure_type` and `prevalence_class` are left UNKNOWN rather than converted into a rate, because a proportion of a disease-ascertained cohort is a different quantity from a population frequency and the schema has no measure type for it.
Show evidence (1 reference)
PMID:31547530 SUPPORT Human Clinical
"In this study, genetic screening was conducted on 8074 Japanese hearing loss patients utilizing massively parallel DNA sequencing to identify individuals with LOXHD1 variants and to assess their phenotypes. A total of 28 affected individuals and 21 LOXHD1 variants were identified, among which 13..."
Numerator, denominator and variant count in one sentence - the only place in the DFNB77 literature where all three are stated together.
Hearing-impaired probands, age-balanced German diagnostic cohort
Unknown Unknown
This record deliberately does not state a population prevalence for DFNB77, because none has been published. What is measurable is LOXHD1's share of *solved* cases in a hearing-loss cohort: 7% of autosomal recessive diagnoses in an age-balanced German cohort of 305 probands where a genetic diagnosis was established in 25% overall. That is a diagnostic-yield figure, not a disease frequency in the population, and the two must not be read as interchangeable - which is why `measure_type` and `prevalence_class` are left UNKNOWN rather than being filled with a number that would answer a different question.
Show evidence (2 references)
PMID:34753855 SUPPORT Human Clinical
"A genetic diagnosis was established for 75 (25%) of the probands that involved 75 causal variants in 35 genes, including 16 novel causal variants and 9 medically significant variant reclassifications."
The denominator for the yield figure - 25% of 305 probands solved.
PMID:34753855 SUPPORT Human Clinical
"Nearly one-quarter of the cases (23%; n = 17) were associated with variants in seven additional genes (TMPRSS3, COL4A3, LOXHD1, EDNRB, MYO6, TECTA, and USH2A)."
Places LOXHD1 in the second tier of contributing genes in that cohort.
🐁

Animal Models

2
samba mouse (ENU-induced Loxhd1 mutant)
The ENU-induced line from which the gene was identified. Its importance is not that it models a known human disease but that it found one: mapping samba to Loxhd1 is what prompted screening of human deafness families and led to DFNB77.
Species
Mouse
Genotype
Loxhd1 ENU-induced point mutation (samba allele)
Publication
PMID:19732867
Pathograph links
Progressive Hair-Cell Degeneration recapitulates fidelity: high Reproduces the human sequence: normal stereociliary development, then perturbed hair-cell function, then hair-cell degeneration - matching the progressive rather than congenital character of the human hearing loss.
Limitations: A mouse point allele standing in for a range of human variants. The correspondence of a particular human genotype's severity to the samba phenotype has not been established, and the human onset range is wide.
Readouts
Hair-cell survival over age
Direction: DECREASED
Interpretation: Degeneration follows functional failure rather than preceding it, which is the ordering the human progressive course requires.
Show evidence (1 reference)
PMID:19732867 SUPPORT Model Organism
"Stereociliary development is unaffected in samba mice, but hair cell function is perturbed and hair cells eventually degenerate."
Reports the histological and functional sequence behind this readout.
Show evidence (1 reference)
PMID:19732867 SUPPORT Model Organism
"We show that hearing loss in the ethylnitrosourea (ENU)-induced samba mouse line is caused by a mutation in Loxhd1."
Establishes the model's genotype and that its hearing loss is Loxhd1-caused, which is what licenses reading its phenotype as informative for the human gene.
Loxhd1 mouse models with tenth PLAT-repeat mutations
Two independent mouse lines used to localise the defect to mechanotransduction rather than to bundle structure. Both sexes were studied.
Species
Mouse
Genotype
Two independent Loxhd1 alleles affecting the 10th PLAT repeat
Publication
PMID:33707295
Pathograph links
Hair-Cell Mechanotransduction Failure with Intact Bundle Architecture measures fidelity: moderate Direct electrophysiological measurement of the failing step, with the structural alternatives measured in the same animals and found normal.
Limitations: Murine, and the alleles are engineered rather than patient-derived. No human hair-cell recording exists for comparison and none is obtainable, so the mechanistic step in the human disease rests on this model.
Readouts
Mechanotransduction current in inner hair cells at postnatal day 11
Direction: DECREASED
Interpretation: The failing step, with a normal first postnatal week as the internal control that dates the onset.
Show evidence (1 reference)
PMID:33707295 SUPPORT Model Organism
"While mechanotransduction currents in mutant inner hair cells (IHCs) were similar to wild-type levels in the first postnatal week, they were severely affected by postnatal day 11."
Reports the electrophysiological measurement behind this readout.
Tip-link number and hair-bundle morphology
Direction: UNCHANGED
Interpretation: A negative result that is doing real work: it excludes a structural cause and is why this node is a transduction failure rather than a bundle defect.
Show evidence (1 reference)
PMID:33707295 SUPPORT Model Organism
"The mechanotransduction defect observed in Loxhd1-mutant IHCs was not accompanied by a morphologic defect of the hair bundle or a reduction in TL number."
Reports the structural measurements behind this readout.
Harmonin and LHFPL5 localisation in the hair bundle
Direction: UNCHANGED
Interpretation: Tip-link complex proteins remain where they belong, so the machinery is present. Together with the current measurement this is what supports "present but not activatable".
Show evidence (1 reference)
PMID:33707295 SUPPORT Model Organism
"we found that two proteins of the upper and lower TL protein complexes (Harmonin and LHFPL5) were maintained in the mutants"
Reports the immunolocalisation measurement behind this readout.
Show evidence (1 reference)
PMID:33707295 SUPPORT Model Organism
"Here, we identified the hearing loss-associated Loxhd1/DFNB77 gene as being required for the mechanotransduction process."
Supports treating this model as informative for the transduction node, and names the human locus explicitly.
{ }

Source YAML

click to show 
name: Autosomal Recessive Nonsyndromic Hearing Loss 77
category: Mendelian
creation_date: "2026-08-30T22:05:00Z"
synonyms:
- DFNB77
- Deafness, autosomal recessive 77
- LOXHD1-related autosomal recessive nonsyndromic hearing loss
- Autosomal recessive nonsyndromic deafness 77
description: >-
  DFNB77 is autosomal recessive nonsyndromic hearing loss caused by biallelic variants in
  LOXHD1, a protein built almost entirely of PLAT (polycystin/lipoxygenase/alpha-toxin) repeats
  and distributed along the length of the hair-cell stereociliary membrane. It was identified by
  going the unusual direction - from a mouse mutant to a human family. The ENU-induced *samba*
  line was mapped to Loxhd1, and the human gene was then screened in deafness families, which is
  how DFNB77 was found.

  The mechanism is the interesting part, and it is specific enough to be worth stating precisely
  rather than as "hair cells degenerate". Stereociliary development is normal in mutant mice.
  The hair bundle is morphologically intact, tip links are present in normal numbers, and the
  upper and lower tip-link complex proteins Harmonin and LHFPL5 are still correctly localised.
  What fails is the mechanotransduction current itself, and only after a delay:
  mechanotransduction in mutant inner hair cells is at wild-type levels through the first
  postnatal week and severely affected by postnatal day 11, tracking the timing of LOXHD1's own
  arrival in the bundle. The machinery is present but not activatable. Hair cells then degenerate
  secondarily.

  That sequence - normal development, then transduction failure, then degeneration - is what
  makes DFNB77 a *progressive* hearing loss rather than a congenital-profound one, and it puts
  the disease in a small class. The founding report names LOXHD1, MYO3A and PJVK as the only
  human genes then linked to progressive autosomal recessive nonsyndromic hearing loss, and
  proposes age-dependent hair-cell failure as their common mechanism.

  Two further things are curated here because they are the sort of detail that gets flattened.
  LOXHD1 variants have been reported in auditory neuropathy spectrum disorder, with preserved
  cochlear microphonic and partial otoacoustic emissions - a presentation a curator expecting
  "sensorineural hearing loss" would not predict. And LOXHD1 is a recurring, non-trivial
  contributor to diagnostic yield in unselected hearing-loss cohorts, not a one-family curiosity.

  Two cohort studies since 2018 have also settled things that would otherwise be left as
  plausible inference, and both settled them negatively. Vestibular function is spared: a
  nine-family Dutch series found no evidence of vestibular involvement, and a screen of 8,074
  Japanese hearing-loss patients found no accompanying symptoms including vestibular
  dysfunction. That matters because LOXHD1 is expressed in vestibular as well as cochlear hair
  cells, so sparing is a finding rather than an absence of interest. And there is no
  genotype-phenotype correlation to be had: the Dutch series looked for one across fifteen
  variants and could not establish it, attributing the inter- and intrafamilial variation to
  modifiers or environment instead.
disease_term:
  preferred_term: autosomal recessive nonsyndromic hearing loss 77
  term:
    id: MONDO:0013119
    label: autosomal recessive nonsyndromic hearing loss 77
parents:
- Nonsyndromic Hearing Loss
notes: >-
  Identifiers. OMIM #613079 (DFNB77) and OMIM 613072 (LOXHD1). These are recorded in prose
  because the schema's `mappings` block carries `mondo_mappings` only and there is no slot for
  an OMIM identifier - the same reason `kb/disorders/Perrault_Syndrome.yaml` lists its subtypes'
  OMIM numbers in a description string.

  Evidence base. The founding report (PMID:19732867) pairs an ENU mouse mutant with a human
  deafness family and is the source of the gene-disease relationship. The mechanism is carried
  by a later study of two Loxhd1 mouse models (PMID:33707295) which is unusually informative
  because of what it rules out - bundle morphology, tip-link number, and tip-link complex
  protein localisation were all checked and all normal. Two cohort papers (PMID:34753855,
  PMID:36472766) supply the frequency and allelic-spectrum context, and one case series
  (PMID:35875410) supplies the auditory-neuropathy presentation.

  What the mouse can and cannot carry here. The mechanotransduction work is entirely murine, and
  the entry marks it INDIRECT wherever it supports a claim about the human disease. What makes
  it more than a model result is that the human gene was found *because* of the mouse: the same
  report that describes samba screened human deafness families on the strength of it and found
  DFNB77. The mouse is not a post-hoc model of a human disease; it is how the human disease was
  identified.

  Not curated here, deliberately. LOXHD1 also carries an association with Fuchs endothelial
  corneal dystrophy. That is a separate allelic phenotype in a different tissue, and no source
  cited here bears on it, so it is mentioned in the gene notes and nowhere else - it is not part
  of the DFNB77 phenotype and should not be inherited into this entry by association.

  No frequency is given for individual phenotypes as a percentage of DFNB77 patients, because no
  cohort of DFNB77 patients has been assembled. The frequencies below describe how often LOXHD1
  accounts for a solved case in unselected hearing-loss cohorts, which is a different quantity
  and is labelled as such.

  Deep research: an OpenScientist report was generated for this disease and is committed
  alongside the entry. It was used as a lead source only - every snippet below is anchored to a
  PMID fetched into `references_cache/` and read directly. It earned its place: the two cohort
  papers that carry the vestibular-sparing finding, the absent genotype-phenotype correlation,
  the Japanese recurrent allele and the Fuchs corneal dystrophy carrier screen (PMID:31547530,
  PMID:29676012) all reached this entry as leads from that report and were then read directly.

  Its own record: 20 of 23 ontology terms resolved, with `HP:0008550` unresolved - a
  confabulated identifier, not used here. `just preflight-dr` returned WARN rather than PASS,
  flagging "rival gene PLAT is mentioned 20 times". That is a false positive of the kind
  described in issue #9847: PLAT here is the polycystin/lipoxygenase/alpha-toxin *domain* that
  LOXHD1 is built from, not the plasminogen activator gene, and the same output line lists MET,
  which is mechanotransduction. The report is on topic.
inheritance:
- name: Autosomal recessive
  description: >-
    Biallelic LOXHD1 variants. Reported as homozygous in consanguineous families and as compound
    heterozygous elsewhere.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:19732867
    reference_title: "Mutations in LOXHD1, an evolutionarily conserved stereociliary protein, disrupt hair cell function in mice and cause progressive hearing loss in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we screened DNA from human families segregating deafness and identified a mutation in LOXHD1, which causes DFNB77, a progressive form of autosomal-recessive nonsyndromic hearing loss (ARNSHL)"
    explanation: Establishes the recessive inheritance and names the locus.
  - reference: PMID:36472766
    reference_title: "Biallelic mutations in pakistani families with autosomal recessive prelingual nonsyndromic hearing loss."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study identified biallelic mutations as the underlying cause of early onset DFNB in six Pakistani families."
    explanation: >-
      Independent confirmation of biallelic inheritance for LOXHD1 among the DFNB genes in this
      cohort.
pathophysiology:
- name: LOXHD1 Loss of Function in Stereocilia
  description: >-
    Biallelic LOXHD1 variants remove or disable a protein consisting entirely of PLAT
    (polycystin/lipoxygenase/alpha-toxin) repeats - fifteen of them - which in other proteins
    bind lipids and proteins. LOXHD1 is distributed along the length of the stereocilia rather
    than concentrated at the tip-link ends, and it is evolutionarily conserved.

    Its arrival in the hair bundle is late. Both published mouse models carry mutations in the
    tenth PLAT repeat, and the functional consequence appears only as postnatal LOXHD1
    expression and localisation in the bundle reach their normal level - which is what makes
    this a maintenance protein rather than a developmental one.
  biological_scale: MOLECULAR
  genes:
  - preferred_term: LOXHD1
    term:
      id: hgnc:26521
      label: LOXHD1
  genetic_context:
    functional_impact_category: LOSS_OF_FUNCTION
    allele_type: VARIANT
    variant_origin: GERMLINE
    zygosity: HOMOZYGOUS
  cellular_components:
  - preferred_term: hair-cell stereocilium membrane
    term:
      id: GO:0032420
      label: stereocilium
  cell_types:
  - preferred_term: cochlear inner hair cell
    term:
      id: CL:0000589
      label: cochlear inner hair cell
  downstream:
  - target: Hair-Cell Mechanotransduction Failure with Intact Bundle Architecture
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:19732867
    reference_title: "Mutations in LOXHD1, an evolutionarily conserved stereociliary protein, disrupt hair cell function in mice and cause progressive hearing loss in humans."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "LOXHD1 consists entirely of PLAT (polycystin/lipoxygenase/alpha-toxin) domains and is expressed along the membrane of mature hair cell stereocilia."
    explanation: The protein's composition and its subcellular location, which together define this node.
  - reference: PMID:33707295
    reference_title: "Loxhd1 Mutations Cause Mechanotransduction Defects in Cochlear Hair Cells."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "LOXHD1 consists of 15 polycystin lipoxygenase α-toxin (PLAT) repeats, which in other proteins can bind lipids and proteins."
    explanation: >-
      The repeat count and the functional class of the repeats. INDIRECT because the inference
      that LOXHD1's repeats bind lipids and proteins is carried over from other PLAT-domain
      proteins rather than demonstrated for LOXHD1 - the authors' own hedge "in other proteins"
      is kept in the quote.
- name: Hair-Cell Mechanotransduction Failure with Intact Bundle Architecture
  description: >-
    The central mechanistic finding, and it is defined as much by what is normal as by what is
    not. Mutant inner hair cells have mechanotransduction currents at wild-type levels through
    the first postnatal week and severely reduced currents by postnatal day 11. Over the same
    interval the hair bundle stays morphologically normal, tip-link number is not reduced, and
    Harmonin and LHFPL5 - proteins of the upper and lower tip-link complexes - remain correctly
    localised.

    The authors' reading is that the transduction machinery is present but not activatable. That
    is a specific claim and it excludes the two obvious alternatives, which is why this entry
    states the exclusions rather than only the positive finding: this is not a bundle
    malformation and it is not a tip-link deficiency.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: cochlear inner hair cell
    term:
      id: CL:0000589
      label: cochlear inner hair cell
  biological_processes:
  - preferred_term: mechanotransduction in cochlear hair cells
    modifier: DECREASED
    term:
      id: GO:0050910
      label: detection of mechanical stimulus involved in sensory perception of sound
  cellular_components:
  - preferred_term: stereocilium bundle
    term:
      id: GO:0032421
      label: stereocilium bundle
  downstream:
  - target: Progressive Hair-Cell Degeneration
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:33707295
    reference_title: "Loxhd1 Mutations Cause Mechanotransduction Defects in Cochlear Hair Cells."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "While mechanotransduction currents in mutant inner hair cells (IHCs) were similar to wild-type levels in the first postnatal week, they were severely affected by postnatal day 11."
    explanation: >-
      The measurement itself, with its timing. INDIRECT for the human disease because the
      recordings are murine; the timing is what links it to the progressive human course.
  - reference: PMID:33707295
    reference_title: "Loxhd1 Mutations Cause Mechanotransduction Defects in Cochlear Hair Cells."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "The mechanotransduction defect observed in Loxhd1-mutant IHCs was not accompanied by a morphologic defect of the hair bundle or a reduction in TL number."
    explanation: >-
      The exclusion that makes this node specific: not a bundle malformation and not a tip-link
      deficiency. Recorded as SUPPORT because it supports this node's claim by ruling out the
      alternatives, and INDIRECT because that is an inference from a negative result.
  - reference: PMID:33707295
    reference_title: "Loxhd1 Mutations Cause Mechanotransduction Defects in Cochlear Hair Cells."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "we found that two proteins of the upper and lower TL protein complexes (Harmonin and LHFPL5) were maintained in the mutants, suggesting that the mechanotransduction machinery was present but not activatable"
    explanation: >-
      The strongest statement of this node's claim, with the authors' hedge "suggesting" kept in
      the quote. INDIRECT for the same reason as above.
- name: Progressive Hair-Cell Degeneration
  description: >-
    Hair cells that develop normally and then fail to transduce do not survive. In samba mice,
    stereociliary development is unaffected, hair-cell function is perturbed, and hair cells
    eventually degenerate. The ordering matters clinically: it is what makes the human hearing
    loss progressive rather than congenital and stable, and it is what defines the therapeutic
    window, if one ever exists, as the interval before degeneration.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: auditory hair cell
    term:
      id: CL:0000202
      label: auditory hair cell
  downstream:
  - target: Progressive Sensorineural Hearing Loss
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:19732867
    reference_title: "Mutations in LOXHD1, an evolutionarily conserved stereociliary protein, disrupt hair cell function in mice and cause progressive hearing loss in humans."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "Stereociliary development is unaffected in samba mice, but hair cell function is perturbed and hair cells eventually degenerate."
    explanation: >-
      States the whole sequence in one sentence - normal development, functional failure, then
      degeneration. INDIRECT for the human disease because the histology is murine.
- name: Vestibular Hair-Cell Sparing
  description: >-
    Vestibular hair cells are spared, and there is a mechanistic reason rather than a
    coincidence. LOXHD1 is expressed in the hair cells of the vestibule as well as the cochlea,
    so the null expectation is vestibular involvement - but vestibular hair cells express only
    reduced amounts of LOXHD1 and are not affected by the mutation in samba mice. The dose
    difference is what makes the disease non-syndromic.

    The clinical correlate is replicated across every series that looked: normal and symmetrical
    vestibular evoked myogenic potentials in a reported proband, no vestibular involvement in a
    nine-family Dutch series, and no accompanying symptoms including vestibular dysfunction in a
    screen of 8,074 Japanese hearing-loss patients.

    This is modelled as a pathophysiology node rather than as a phenotype because the schema has
    no way to record a phenotype as explicitly absent - `FrequencyEnum` has no EXCLUDED value
    (HP:0040285) and `Phenotype` has no negation slot. An earlier revision of this entry did
    record it as a phenotype bound to `HP:0001751` "Abnormal vestibular function", which is the
    opposite of the finding and would have exported as a claim that DFNB77 causes vestibular
    dysfunction. That was wrong and is the reason the rule "no term beats a bad one" exists. See
    issue #10190. Following the pattern of "Preserved Zona Glomerulosa Mineralocorticoid
    Production" in `kb/disorders/Familial_Glucocorticoid_Deficiency.yaml`.

    This node is deliberately isolated - nothing points to it and it points nowhere. That is
    what a sparing claim is: the LOXHD1 lesion does not cause the sparing, it fails to reach
    the tissue, so an incoming `downstream` edge would assert a causal relation that runs the
    wrong way. The node exists to record that the vestibular arm was looked at and found
    intact, which is what makes the disease non-syndromic.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: vestibular hair cell
    term:
      id: CL:0000609
      label: vestibular hair cell
  evidence:
  - reference: PMID:35875410
    reference_title: "Mutations in LOXHD1 gene can cause auditory neuropathy spectrum disorder."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "vestibular hair cells only expressed reduced amounts of LOXHD1 and are not affected by the mutation in the samba mice, which corroborate the lack of vestibular and balance issues in the developing siblings and presence of normal VEMP in the proband"
    explanation: >-
      The mechanistic explanation and the clinical corroboration in one sentence. Graded
      MODEL_ORGANISM because the expression-level claim it rests on is murine, and INDIRECT
      because this paper is reporting Grillet's result rather than measuring it. The quote is
      cut before the sentence's inline numeric citation markers, which the reference validator
      strips from the query but not from the cached text.
  - reference: PMID:35875410
    reference_title: "Mutations in LOXHD1 gene can cause auditory neuropathy spectrum disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical reports of LOXHD1 mutations have not revealed any vestibular symptoms in affected individuals."
    explanation: >-
      The literature-wide clinical statement, which is what makes the sparing a general property
      of the disease rather than an observation in one series.
  - reference: PMID:29676012
    reference_title: "Further audiovestibular characterization of DFNB77, caused by deleterious variants in LOXHD1, and investigation into the involvement of Fuchs corneal dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There was no evidence for involvement of the vestibular system."
    explanation: >-
      The human negative, from a series assembled specifically to characterise the
      audiovestibular phenotype - so it comes from a study designed to find involvement if it
      were there.
  - reference: PMID:31547530
    reference_title: "Mutational Spectrum and Clinical Features of Patients with LOXHD1 Variants Identified in an 8074 Hearing Loss Patient Cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "No accompanying symptoms, including vestibular dysfunction, with hearing loss were detected in this study."
    explanation: >-
      Independent replication of the human negative in a much larger screen, which is why this
      is recorded as established rather than as one series' observation.
- name: Progressive Sensorineural Hearing Loss
  description: >-
    The clinical endpoint. Hearing loss that is progressive rather than static, which the
    founding report places in a class of three genes - LOXHD1, MYO3A and PJVK - all of which are
    required for hair-cell function rather than for hair-cell development, and for which it
    proposes age-dependent hair-cell failure as the shared mechanism.
  biological_scale: ORGANISM
  downstream:
  - target: Progressive Sensorineural Hearing Impairment
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:19732867
    reference_title: "Mutations in LOXHD1, an evolutionarily conserved stereociliary protein, disrupt hair cell function in mice and cause progressive hearing loss in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LOXHD1, MYO3a, and PJVK are the only human genes to date linked to progressive ARNSHL. These three genes are required for hair cell function, suggesting that age-dependent hair cell failure is a common mechanism for progressive ARNSHL."
    explanation: >-
      The clinical class this disease belongs to and the mechanism the authors propose for it,
      with their hedge "suggesting" preserved.
phenotypes:
- name: Progressive Sensorineural Hearing Impairment
  category: Auditory
  description: >-
    The defining feature: sensorineural hearing loss that worsens over time rather than being
    static from birth. Progression is what distinguishes DFNB77 from most autosomal recessive
    nonsyndromic hearing loss, and it follows directly from the mechanism - hair cells that
    develop normally, lose transduction, and then degenerate.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Progressive sensorineural hearing impairment
    term:
      id: HP:0000408
      label: Progressive sensorineural hearing impairment
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:19732867
    reference_title: "Mutations in LOXHD1, an evolutionarily conserved stereociliary protein, disrupt hair cell function in mice and cause progressive hearing loss in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we screened DNA from human families segregating deafness and identified a mutation in LOXHD1, which causes DFNB77, a progressive form of autosomal-recessive nonsyndromic hearing loss (ARNSHL)"
    explanation: Names the phenotype and its progressive character in the founding human family.
- name: Prelingual Onset Hearing Loss
  category: Auditory
  description: >-
    Early-onset presentation, reported in Pakistani families where LOXHD1 was among the genes
    solving prelingual-onset DFNB. Onset in DFNB77 is not uniform across reports - the German
    cohort found LOXHD1 among the genes associated with *late* hearing-loss onset in single
    cases - so both ends are recorded rather than a single onset being asserted.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Prelingual sensorineural hearing impairment
    term:
      id: HP:0000399
      label: Prelingual sensorineural hearing impairment
    onset:
      onset_category: CONGENITAL
  evidence:
  - reference: PMID:36472766
    reference_title: "Biallelic mutations in pakistani families with autosomal recessive prelingual nonsyndromic hearing loss."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identified eight pathogenic or likely pathogenic mutations in LOXHD1, GJB2, SLC26A4, MYO15A, and TMC1 from six families."
    explanation: >-
      Places LOXHD1 among the genes solving prelingual-onset DFNB in this cohort, which is the
      basis for recording an early-onset presentation.
  - reference: PMID:31547530
    reference_title: "Mutational Spectrum and Clinical Features of Patients with LOXHD1 Variants Identified in an 8074 Hearing Loss Patient Cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with LOXHD1 variations mostly showed early onset hearing loss and presented different progression rates."
    explanation: >-
      The frequency-bearing statement behind the FREQUENT band - "mostly" in a 28-patient
      cohort. Note that the same sentence records variable progression, which is why onset is
      banded but rate of progression is not.
  - reference: PMID:34753855
    reference_title: "Diagnostic Yield of Targeted Hearing Loss Gene Panel Sequencing in a Large German Cohort With a Balanced Age Distribution from a Single Diagnostic Center: An Eight-year Study."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Four autosomal-recessive genes demonstrated an association with late hearing loss onset in single cases (TMPRSS3, GJB2, LOXHD1, and SLC26A4)."
    explanation: >-
      Refutes prelingual onset as an obligate feature: in an age-balanced cohort LOXHD1 also
      turned up among the late-onset diagnoses. Recorded against this phenotype rather than
      omitted, so a reader does not take early onset as a rule-out for late presentation.
- name: Auditory Neuropathy Spectrum Disorder Presentation
  category: Auditory
  description: >-
    A presentation that a "sensorineural hearing loss" label would not predict. Three related
    children with LOXHD1 variants had auditory neuropathy spectrum disorder, with a cochlear
    microphonic and/or partial otoacoustic emissions present early in life - meaning some
    cochlear hair-cell function survived while the auditory response was disordered. Two were
    successfully managed with cochlear implants.

    This is consistent with the mechanism rather than in tension with it: LOXHD1 mutant hair
    cells are present and structurally normal but not transducing, which is exactly the
    substrate for a preserved cochlear microphonic with a disordered response.

    Frequency is VERY_RARE rather than OCCASIONAL: the basis is three related children from one
    family, and the 28-patient Japanese cohort reported no such presentation. The report's own
    authors note that no previous DFNB77 study measured outer-hair-cell function, so ANSD may
    simply not have been looked for elsewhere - which argues for leaving the band low rather
    than raising it on an untested suspicion that it is commoner.
  frequency: VERY_RARE
  phenotype_term:
    preferred_term: Auditory Neuropathy Pattern
    term:
      id: HP:0006958
      label: Abnormal auditory evoked potentials
  evidence:
  - reference: PMID:35875410
    reference_title: "Mutations in LOXHD1 gene can cause auditory neuropathy spectrum disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All three subjects had evidence of some, albeit few, functioning cochlear hair cells as revealed by the presence of a cochlear microphonic and/or partial otoacoustic emissions early in life."
    explanation: >-
      The audiological finding that defines this presentation, and the one that shows residual
      hair-cell function. Bound to Abnormal auditory evoked potentials rather than to the
      generic sensorineural-hearing-impairment term, because the abnormal-ABR-with-preserved-OAE
      signature is what distinguishes ANSD from the entry's main phenotype rather than
      restating it - the same binding used for "Auditory Neuropathy Pattern" in
      `kb/disorders/Perrault_Syndrome.yaml`.
  - reference: PMID:35875410
    reference_title: "Mutations in LOXHD1 gene can cause auditory neuropathy spectrum disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To our knowledge, this is the first association between LOXHD1 mutations and ANSD in two patients who have been successfully managed with cochlear implants."
    explanation: >-
      Establishes the association as novel at the time of reporting and records the management
      outcome, which is why this presentation matters clinically rather than only descriptively.
genetic:
- name: LOXHD1
  notes: >-
    Encodes a large protein composed entirely of fifteen PLAT
    (polycystin/lipoxygenase/alpha-toxin) repeats, distributed along the stereociliary membrane
    of mature hair cells. Both published mouse models carry mutations in the tenth PLAT repeat.

    The gene was found from the mouse, not from the human. The ENU-induced samba line was mapped
    to Loxhd1 first, and human deafness families were then screened on the strength of it - which
    is worth stating because it is the reverse of the usual order and it is why the mouse work
    carries more weight here than a post-hoc model normally would.

    LOXHD1 is not a rare-in-practice gene. In an age-balanced German cohort of 305
    hearing-impaired probands it was among seven genes accounting for 23% of solved cases, and
    among autosomal recessive genes it tied with TMPRSS3 at 7% of that group. Novel compound
    heterozygous alleles continue to be reported.

    Separately, heterozygous deleterious LOXHD1 missense variants have been associated with
    late-onset Fuchs endothelial corneal dystrophy. This is worth stating precisely rather than
    as a vague allelic caveat, because it has been tested: carriers within nine DFNB77 families
    were screened for FCD and none showed pre-clinical or clinical signs. So the reported
    heterozygous FCD association did not reproduce in DFNB77 carriers, and a DFNB77 family should
    not be counselled about corneal risk on the strength of it.

    Population structure. A recurrent splice variant c.4212+1G>A accounts for 18 of 28 affected
    individuals identified in a screen of 8,074 Japanese hearing-loss patients, and haplotype
    analysis indicates it arose at a mutational hot spot in multiple ancestors rather than
    descending from one founder - which is an unusual and specific finding, and the reason this
    is not described here as a founder allele.
  relationship_type: CAUSATIVE
  gene_term:
    preferred_term: LOXHD1
    term:
      id: hgnc:26521
      label: LOXHD1
  evidence:
  - reference: PMID:19732867
    reference_title: "Mutations in LOXHD1, an evolutionarily conserved stereociliary protein, disrupt hair cell function in mice and cause progressive hearing loss in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Based on the studies in mice, we screened DNA from human families segregating deafness and identified a mutation in LOXHD1, which causes DFNB77"
    explanation: >-
      The gene-disease relationship and, in the same sentence, the mouse-first route by which it
      was established.
  - reference: PMID:34753855
    reference_title: "Diagnostic Yield of Targeted Hearing Loss Gene Panel Sequencing in a Large German Cohort With a Balanced Age Distribution from a Single Diagnostic Center: An Eight-year Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At the single-gene level, causative variants in GJB2 were the most common cause among autosomal-recessive genes (45%), followed by MYO15A and SLC26A4 (both 10%), TMPRSS3 and LOXHD1 (both 7%)."
    explanation: >-
      Quantifies LOXHD1's share among autosomal recessive diagnoses in an unselected cohort,
      which is what establishes it as a routine contributor rather than a single-family gene.
  variants:
  - name: c.4212+1G>A
    description: >-
      Recurrent splice-donor variant found in 18 of 28 LOXHD1-positive individuals in a Japanese
      hearing-loss cohort and reported only in Japanese patients. Haplotype analysis indicates a
      mutational hot spot arising in multiple ancestors rather than a single founder event.
    evidence:
    - reference: PMID:31547530
      reference_title: "Mutational Spectrum and Clinical Features of Patients with LOXHD1 Variants Identified in an 8074 Hearing Loss Patient Cohort."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A recurrent variant c.4212 + 1G > A, only reported in Japanese patients, was detected in 18 individuals. Haplotype analysis implied that this variation occurred in a mutational hot spot, and that multiple ancestors of Japanese population had this variation."
      explanation: >-
        The allele, its frequency in that cohort, its population restriction, and the haplotype
        result that distinguishes a hot spot from a founder effect.
  - name: p.D278Y and p.D1219E compound heterozygous pair
    description: >-
      Novel compound heterozygous LOXHD1 alleles reported in a Pakistani family with prelingual
      autosomal recessive nonsyndromic hearing loss. Both are missense changes at conserved
      residues.
    evidence:
    - reference: PMID:36472766
      reference_title: "Biallelic mutations in pakistani families with autosomal recessive prelingual nonsyndromic hearing loss."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The four missense or start-loss mutations were located at well conserved residues, and most in silico analysis predicted their pathogenicity."
      explanation: >-
        Supports the conservation and predicted pathogenicity of the missense alleles reported in
        that cohort. The allele designations themselves are given in square-bracketed notation in
        the source sentence, which the reference validator strips, so they are carried in this
        variant's name and description instead.
prevalence:
- population: Japanese hearing-loss patients screened by massively parallel sequencing
  measure_type: UNKNOWN
  prevalence_class: UNKNOWN
  notes: >-
    The best denominator published for this disease: 28 affected individuals carrying 21 LOXHD1
    variants, from a screen of 8,074 Japanese hearing-loss patients. That is roughly 0.35% of an
    ascertained hearing-loss cohort, not a population prevalence, and it is not transferable to
    other ancestries - 18 of the 28 carry one recurrent splice variant seen only in Japanese
    patients. `measure_type` and `prevalence_class` are left UNKNOWN rather than converted into a
    rate, because a proportion of a disease-ascertained cohort is a different quantity from a
    population frequency and the schema has no measure type for it.
  evidence:
  - reference: PMID:31547530
    reference_title: "Mutational Spectrum and Clinical Features of Patients with LOXHD1 Variants Identified in an 8074 Hearing Loss Patient Cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this study, genetic screening was conducted on 8074 Japanese hearing loss patients utilizing massively parallel DNA sequencing to identify individuals with LOXHD1 variants and to assess their phenotypes. A total of 28 affected individuals and 21 LOXHD1 variants were identified, among which 13 were novel variants."
    explanation: >-
      Numerator, denominator and variant count in one sentence - the only place in the DFNB77
      literature where all three are stated together.
- population: Hearing-impaired probands, age-balanced German diagnostic cohort
  measure_type: UNKNOWN
  prevalence_class: UNKNOWN
  notes: >-
    This record deliberately does not state a population prevalence for DFNB77, because none has
    been published. What is measurable is LOXHD1's share of *solved* cases in a hearing-loss
    cohort: 7% of autosomal recessive diagnoses in an age-balanced German cohort of 305 probands
    where a genetic diagnosis was established in 25% overall. That is a diagnostic-yield figure,
    not a disease frequency in the population, and the two must not be read as interchangeable -
    which is why `measure_type` and `prevalence_class` are left UNKNOWN rather than being filled
    with a number that would answer a different question.
  evidence:
  - reference: PMID:34753855
    reference_title: "Diagnostic Yield of Targeted Hearing Loss Gene Panel Sequencing in a Large German Cohort With a Balanced Age Distribution from a Single Diagnostic Center: An Eight-year Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A genetic diagnosis was established for 75 (25%) of the probands that involved 75 causal variants in 35 genes, including 16 novel causal variants and 9 medically significant variant reclassifications."
    explanation: The denominator for the yield figure - 25% of 305 probands solved.
  - reference: PMID:34753855
    reference_title: "Diagnostic Yield of Targeted Hearing Loss Gene Panel Sequencing in a Large German Cohort With a Balanced Age Distribution from a Single Diagnostic Center: An Eight-year Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nearly one-quarter of the cases (23%; n = 17) were associated with variants in seven additional genes (TMPRSS3, COL4A3, LOXHD1, EDNRB, MYO6, TECTA, and USH2A)."
    explanation: Places LOXHD1 in the second tier of contributing genes in that cohort.
progression:
- phase: Onset
  age_range: prelingual to late onset
  notes: >-
    Onset is not consistent across reports and the entry does not pick one. Pakistani families
    with LOXHD1 among the solved genes had prelingual onset; the age-balanced German cohort found
    LOXHD1 among genes associated with late hearing-loss onset in single cases. The mouse data
    give a mechanistic reason to expect variability rather than a fixed onset: the defect appears
    when LOXHD1 reaches its normal level in the bundle, so anything that shifts residual protein
    function shifts the timing.
  evidence:
  - reference: PMID:34753855
    reference_title: "Diagnostic Yield of Targeted Hearing Loss Gene Panel Sequencing in a Large German Cohort With a Balanced Age Distribution from a Single Diagnostic Center: An Eight-year Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Four autosomal-recessive genes demonstrated an association with late hearing loss onset in single cases (TMPRSS3, GJB2, LOXHD1, and SLC26A4)."
    explanation: The late-onset end of the reported range.
- phase: Established disease
  notes: >-
    Progressive. The founding report classifies DFNB77 as one of the few progressive forms of
    autosomal recessive nonsyndromic hearing loss, and the mouse mechanism supplies the reason:
    hair cells fail functionally and then degenerate, so hearing worsens with age rather than
    being fixed at its initial level. No longitudinal audiometric series for DFNB77 patients has
    been published, so the rate of progression is not characterised.
  evidence:
  - reference: PMID:19732867
    reference_title: "Mutations in LOXHD1, an evolutionarily conserved stereociliary protein, disrupt hair cell function in mice and cause progressive hearing loss in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LOXHD1, MYO3a, and PJVK are the only human genes to date linked to progressive ARNSHL."
    explanation: Places DFNB77 in the progressive class of ARNSHL.
diagnosis:
- name: Hearing Loss Gene Panel or Exome Sequencing
  description: >-
    DFNB77 is nonsyndromic, so there is no clinical feature that points at LOXHD1 specifically;
    diagnosis is by sequencing. LOXHD1 is on contemporary hearing-loss panels and is a routine
    contributor to yield, so panel testing rather than exome is usually sufficient. Yield in an
    unselected cohort is strongly phenotype-dependent, which is worth knowing before ordering:
    early onset with a recessive family history and higher-grade loss reached 60%, while late
    onset and lower-grade loss yielded significantly fewer diagnoses.
  evidence:
  - reference: PMID:34753855
    reference_title: "Diagnostic Yield of Targeted Hearing Loss Gene Panel Sequencing in a Large German Cohort With a Balanced Age Distribution from a Single Diagnostic Center: An Eight-year Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A positive family history of autosomal-recessive inheritance in combination with early onset and higher grades of hearing loss significantly increased the solve rate up to 60%, while late onset and lower grades of hearing loss yielded significantly fewer diagnoses."
    explanation: >-
      The phenotype-dependence of diagnostic yield, which is the practical guidance a clinician
      needs before testing.
  - reference: PMID:34753855
    reference_title: "Diagnostic Yield of Targeted Hearing Loss Gene Panel Sequencing in a Large German Cohort With a Balanced Age Distribution from a Single Diagnostic Center: An Eight-year Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Targeted hearing loss gene panel analysis proved to be an effective tool for ensuring an appropriate diagnostic yield in a routine clinical setting including the identification of novel variants and medically significant reclassifications."
    explanation: Supports panel sequencing as the routine diagnostic modality for this class of disease.
- name: Audiological Testing Including Otoacoustic Emissions and Cochlear Microphonic
  description: >-
    Standard audiometry plus otoacoustic emissions, auditory brainstem responses and cochlear
    microphonic. The reason to specify the full battery rather than audiometry alone is the
    auditory-neuropathy presentation: in the reported LOXHD1 ANSD children, a cochlear
    microphonic and partial otoacoustic emissions were present early in life, which is the
    finding that identifies ANSD and changes management. An audiogram alone would not have shown
    it.
  evidence:
  - reference: PMID:35875410
    reference_title: "Mutations in LOXHD1 gene can cause auditory neuropathy spectrum disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "They were assessed with a standard clinical test battery including distortion otoacoustic emissions, auditory brainstem responses and audiometry."
    explanation: The test battery used, and the one that made the ANSD presentation visible.
treatments:
- name: Hearing Aid Amplification
  description: >-
    First-line intervention and, for a disease whose reported severity runs from mild to
    profound, the one most patients receive. In the reported LOXHD1 auditory-neuropathy family
    all three children were fitted early - at 9 months, at 7 weeks, and at 6 months - and the
    outcomes diverged in a way worth recording: the cousin's aided thresholds were in the mild
    range at three and a half years, while the two sisters showed discomfort with amplification
    and limited aided response and went on to implantation.

    That divergence is the practical content of this entry's progression section. Amplification
    is the right starting point, and progression means it may stop being sufficient, so aided
    testing has to be repeated rather than treated as a settled result.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: hearing aid amplification
    term:
      id: NCIT:C15315
      label: Rehabilitation
    qualifiers:
    - predicate:
        preferred_term: medical device
        term:
          id: NCIT:C16830
          label: Medical Device
      value:
        preferred_term: hearing aid
        term:
          id: NCIT:C183182
          label: Hearing Aid
  target_mechanisms:
  - target: Progressive Sensorineural Hearing Loss
    description: >-
      Compensates for the threshold loss. It does not act on the transduction defect or slow
      the hair-cell degeneration driving it.
  notes: >-
    On the action term: this binds NCIT:C15315 Rehabilitation where the closest existing
    analogue, `Otofacial_Neurodevelopmental_Syndrome`, binds NCIT:C49236 Therapeutic Procedure.
    The divergence is deliberate. Fitting and adjusting amplification, with repeated aided
    testing as the loss progresses, is auditory rehabilitation rather than a generic therapeutic
    procedure, and Rehabilitation is the more specific of the two available C25218 descendants.
    The device itself is carried in the qualifier either way.
  evidence:
  - reference: PMID:35875410
    reference_title: "Mutations in LOXHD1 gene can cause auditory neuropathy spectrum disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The cousin proband was fitted with hearing aids at 6 months of age."
    explanation: >-
      The one reported case where amplification alone gave a good aided outcome - his aided pure
      tone thresholds at three and a half years were in the mild range with an aided SRT of
      25 dB. That clause is not quoted because the source renders the age with a fraction
      character the reference validator cannot match.
  - reference: PMID:35875410
    reference_title: "Mutations in LOXHD1 gene can cause auditory neuropathy spectrum disorder."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "She was bilaterally fitted with loaner hearing aids at 9 months. She quickly displayed signs of discomfort with louder sounds and the overall gain and output limit were subsequently decreased for both hearing aids."
    explanation: >-
      Refutes amplification as sufficient in the severe end of the reported spectrum. Recorded
      against this treatment rather than omitted, because both outcomes came from the same
      three-child family and presenting only the good one would misrepresent it.
- name: Cochlear Implantation
  description: >-
    Two of the three reported LOXHD1 auditory-neuropathy children were successfully managed with
    cochlear implants. This is a reasonable expectation on mechanism as well as on report: the
    lesion is at the hair-cell transduction step, upstream of the spiral ganglion and auditory
    nerve, so direct electrical stimulation bypasses it.

    Note the treatment term binds the clinical action, not the device. `NCIT:C157820` "Cochlear
    Implant" names the equipment and has no `NCIT:C25218` ancestor, so it cannot sit in a
    `TreatmentTerm`; it is attached as a qualifier instead, which keeps the device concept
    queryable.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: cochlear device implantation
    term:
      id: NCIT:C15329
      label: Surgical Procedure
    qualifiers:
    - predicate:
        preferred_term: medical device
        term:
          id: NCIT:C16830
          label: Medical Device
      value:
        preferred_term: cochlear implant
        term:
          id: NCIT:C157820
          label: Cochlear Implant
  target_mechanisms:
  - target: Hair-Cell Mechanotransduction Failure with Intact Bundle Architecture
    description: >-
      Bypasses the failed step rather than correcting it. The implant stimulates the auditory
      nerve directly, so it does not depend on hair-cell transduction.

      One caveat on that reasoning, which the outcomes so far do not resolve: the samba mouse
      shows some spiral ganglion neuron loss, thought to be secondary to hair-cell damage rather
      than a primary LOXHD1 effect. If that holds in humans, the target the implant stimulates
      is itself degenerating slowly, and long-term outcome could depend on implanting before it
      does. The reported patients argue against this mattering much in practice - one is a
      normal-audiogram, 100%-word-score implant user eight years on - but two patients is not a
      basis for a claim about implant timing.
  evidence:
  - reference: PMID:35875410
    reference_title: "Mutations in LOXHD1 gene can cause auditory neuropathy spectrum disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To our knowledge, this is the first association between LOXHD1 mutations and ANSD in two patients who have been successfully managed with cochlear implants."
    explanation: >-
      The reported outcome. Two patients is a small basis, and the entry does not present this as
      an established outcome rate for DFNB77 - only that implantation succeeded where it was
      tried and reported.
  - reference: PMID:35875410
    reference_title: "Mutations in LOXHD1 gene can cause auditory neuropathy spectrum disorder."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "presented 2 patients with severe-profound bilateral sensorineural hearing loss due to LOXHD1 mutations who also benefited from cochlear implants."
    explanation: >-
      An independent group's implant outcome in LOXHD1 patients, which takes the basis beyond
      one family. INDIRECT because it reaches this entry as a citation inside the paper being
      quoted rather than from the original report.
  - reference: PMID:35875410
    reference_title: "Mutations in LOXHD1 gene can cause auditory neuropathy spectrum disorder."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "observed in his study some spiral ganglion neuron loss, thought to be a secondary consequence of hair cell damage"
    explanation: >-
      The caveat on the "the lesion is upstream of the spiral ganglion" reasoning. Graded
      MODEL_ORGANISM because the observation is in samba mice, and INDIRECT because this paper
      reports it from Grillet rather than measuring it.
- name: Genetic Counseling
  description: >-
    Autosomal recessive with a 25% recurrence risk. Counselling for DFNB77 has to carry the
    progression: unlike most autosomal recessive nonsyndromic hearing loss, this one worsens, so
    a child's initial audiogram is not their final one and follow-up audiometry is part of the
    plan rather than an optional extra.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:19732867
    reference_title: "Mutations in LOXHD1, an evolutionarily conserved stereociliary protein, disrupt hair cell function in mice and cause progressive hearing loss in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LOXHD1, MYO3a, and PJVK are the only human genes to date linked to progressive ARNSHL."
    explanation: >-
      The progression that counselling has to convey, and the reason DFNB77 is counselled
      differently from a static recessive hearing loss.
animal_models:
- name: samba mouse (ENU-induced Loxhd1 mutant)
  species: Mouse
  genotype: Loxhd1 ENU-induced point mutation (samba allele)
  publication: PMID:19732867
  description: >-
    The ENU-induced line from which the gene was identified. Its importance is not that it models
    a known human disease but that it found one: mapping samba to Loxhd1 is what prompted
    screening of human deafness families and led to DFNB77.
  modeled_mechanisms:
  - target: Progressive Hair-Cell Degeneration
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Reproduces the human sequence: normal stereociliary development, then perturbed hair-cell
      function, then hair-cell degeneration - matching the progressive rather than congenital
      character of the human hearing loss.
    limitations: >-
      A mouse point allele standing in for a range of human variants. The correspondence of a
      particular human genotype's severity to the samba phenotype has not been established, and
      the human onset range is wide.
    readouts:
    - name: Hair-cell survival over age
      target: Progressive Hair-Cell Degeneration
      direction: DECREASED
      interpretation: >-
        Degeneration follows functional failure rather than preceding it, which is the ordering
        the human progressive course requires.
      evidence:
      - reference: PMID:19732867
        reference_title: "Mutations in LOXHD1, an evolutionarily conserved stereociliary protein, disrupt hair cell function in mice and cause progressive hearing loss in humans."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Stereociliary development is unaffected in samba mice, but hair cell function is perturbed and hair cells eventually degenerate."
        explanation: Reports the histological and functional sequence behind this readout.
    evidence:
    - reference: PMID:19732867
      reference_title: "Mutations in LOXHD1, an evolutionarily conserved stereociliary protein, disrupt hair cell function in mice and cause progressive hearing loss in humans."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We show that hearing loss in the ethylnitrosourea (ENU)-induced samba mouse line is caused by a mutation in Loxhd1."
      explanation: >-
        Establishes the model's genotype and that its hearing loss is Loxhd1-caused, which is
        what licenses reading its phenotype as informative for the human gene.
- name: Loxhd1 mouse models with tenth PLAT-repeat mutations
  species: Mouse
  genotype: Two independent Loxhd1 alleles affecting the 10th PLAT repeat
  publication: PMID:33707295
  description: >-
    Two independent mouse lines used to localise the defect to mechanotransduction rather than to
    bundle structure. Both sexes were studied.
  modeled_mechanisms:
  - target: Hair-Cell Mechanotransduction Failure with Intact Bundle Architecture
    relationship: MEASURES
    fidelity: MODERATE
    description: >-
      Direct electrophysiological measurement of the failing step, with the structural
      alternatives measured in the same animals and found normal.
    limitations: >-
      Murine, and the alleles are engineered rather than patient-derived. No human hair-cell
      recording exists for comparison and none is obtainable, so the mechanistic step in the
      human disease rests on this model.
    readouts:
    - name: Mechanotransduction current in inner hair cells at postnatal day 11
      target: Hair-Cell Mechanotransduction Failure with Intact Bundle Architecture
      direction: DECREASED
      interpretation: >-
        The failing step, with a normal first postnatal week as the internal control that dates
        the onset.
      evidence:
      - reference: PMID:33707295
        reference_title: "Loxhd1 Mutations Cause Mechanotransduction Defects in Cochlear Hair Cells."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "While mechanotransduction currents in mutant inner hair cells (IHCs) were similar to wild-type levels in the first postnatal week, they were severely affected by postnatal day 11."
        explanation: Reports the electrophysiological measurement behind this readout.
    - name: Tip-link number and hair-bundle morphology
      target: Hair-Cell Mechanotransduction Failure with Intact Bundle Architecture
      direction: UNCHANGED
      interpretation: >-
        A negative result that is doing real work: it excludes a structural cause and is why this
        node is a transduction failure rather than a bundle defect.
      evidence:
      - reference: PMID:33707295
        reference_title: "Loxhd1 Mutations Cause Mechanotransduction Defects in Cochlear Hair Cells."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "The mechanotransduction defect observed in Loxhd1-mutant IHCs was not accompanied by a morphologic defect of the hair bundle or a reduction in TL number."
        explanation: Reports the structural measurements behind this readout.
    - name: Harmonin and LHFPL5 localisation in the hair bundle
      target: Hair-Cell Mechanotransduction Failure with Intact Bundle Architecture
      direction: UNCHANGED
      interpretation: >-
        Tip-link complex proteins remain where they belong, so the machinery is present. Together
        with the current measurement this is what supports "present but not activatable".
      evidence:
      - reference: PMID:33707295
        reference_title: "Loxhd1 Mutations Cause Mechanotransduction Defects in Cochlear Hair Cells."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "we found that two proteins of the upper and lower TL protein complexes (Harmonin and LHFPL5) were maintained in the mutants"
        explanation: Reports the immunolocalisation measurement behind this readout.
    evidence:
    - reference: PMID:33707295
      reference_title: "Loxhd1 Mutations Cause Mechanotransduction Defects in Cochlear Hair Cells."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Here, we identified the hearing loss-associated Loxhd1/DFNB77 gene as being required for the mechanotransduction process."
      explanation: >-
        Supports treating this model as informative for the transduction node, and names the human
        locus explicitly.
discussions:
- discussion_id: dfnb77_no_genotype_phenotype_correlation
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Severity and rate of progression in DFNB77 vary widely within families carrying the same
    variants. If the LOXHD1 genotype does not predict them, what does?
  attaches_to:
  - genetic#LOXHD1
  - phenotypes#Progressive Sensorineural Hearing Impairment
  - progression#Onset
  rationale: >-
    Two independent groups looked for a genotype-phenotype correlation and neither found one.

    Established: the hearing phenotype varies in severity and progression both between and
    within families; fifteen pathogenic variants across nine Dutch families gave no relationship
    between variant type or position and severity or progression; a Japanese cohort of 28
    individuals, 18 of them sharing one recurrent splice variant, likewise showed different
    progression rates. The intrafamilial part is the sharp end - siblings with identical
    genotypes diverge, so ancestry and allele are both controlled and the variation survives.

    Not established: the cause. Both groups reach for the same pair of candidates and neither
    tests them - the Dutch series hypothesises environmental factors or genetic modifiers, and
    the Japanese cohort speculates the same. No modifier locus has been proposed, and no
    environmental exposure has been examined. Noise exposure is the obvious candidate for a
    disease of progressive hair-cell degeneration and, as far as the sources cited here go,
    nobody has asked.

    This matters for counselling more than for mechanism. A family given a molecular diagnosis
    wants to know how bad it will get, and the honest answer is that the genotype does not say.
  evidence:
  - reference: PMID:29676012
    reference_title: "Further audiovestibular characterization of DFNB77, caused by deleterious variants in LOXHD1, and investigation into the involvement of Fuchs corneal dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a clear correlation between the type or location of the variant and the severity or progression of HI could not be established. We hypothesize that environmental factors or genetic modifiers are responsible for phenotypic differences."
    explanation: >-
      The negative result and the authors' own untested explanation for it, quoted together
      because the hypothesis is doing no work until somebody tests it.
  - reference: PMID:31547530
    reference_title: "Mutational Spectrum and Clinical Features of Patients with LOXHD1 Variants Identified in an 8074 Hearing Loss Patient Cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with LOXHD1 variations mostly showed early onset hearing loss and presented different progression rates. We speculated that the varying severities and progression rates of hearing loss are the result of environmental and/or other genetic factors."
    explanation: >-
      Independent replication of both the observation and the untested explanation, in a much
      larger cohort dominated by a single shared allele.
  proposed_experiments:
  - experiment_id: exp_dfnb77_modifier_and_exposure_study
    name: Modifier and noise-exposure study in the Japanese c.4212+1G>A cohort
    description: >-
      The 18 individuals homozygous or compound heterozygous for the same recurrent splice
      variant are an unusually clean natural experiment: allele held constant, ancestry largely
      held constant, phenotype varying. Genotype them for known hearing-loss modifier loci and
      collect lifetime noise-exposure and ototoxic-drug history, then test both against
      audiometric slope.
    would_support:
    - genetic#LOXHD1
    supporting_outcome:
    - >-
      Progression rate tracks a modifier locus or a measured exposure, converting an unexplained
      variance into a counselling-relevant and potentially modifiable factor.
    refuting_outcome:
    - >-
      Neither modifiers nor exposure explain the variance in a cohort sharing one allele,
      indicating the variability is stochastic at the level of hair-cell survival and that no
      prognostic statement is available at diagnosis.
- discussion_id: dfnb77_how_loxhd1_gates_transduction
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    The mechanotransduction machinery is present and correctly localised in LOXHD1-mutant hair
    cells but does not conduct. What does LOXHD1 do that the assembled machinery needs?
  attaches_to:
  - pathophysiology#LOXHD1 Loss of Function in Stereocilia
  - pathophysiology#Hair-Cell Mechanotransduction Failure with Intact Bundle Architecture
  rationale: >-
    This is a well-posed gap rather than a general absence of knowledge, because the obvious
    answers have been tested and excluded.

    Established: LOXHD1 is fifteen PLAT repeats distributed along the stereociliary membrane; it
    arrives late in postnatal bundle development; mechanotransduction currents are normal in the
    first postnatal week and severely reduced by day 11, tracking that arrival; the hair bundle
    is morphologically normal; tip-link number is not reduced; Harmonin and LHFPL5 are correctly
    localised.

    Excluded by those measurements: a developmental bundle malformation, a tip-link deficiency,
    and a failure to assemble the tip-link protein complexes.

    Not established: the actual function. The generic positional evidence is weak - PLAT repeats
    bind lipids and proteins *in other proteins*, an inference from domain class rather than a
    demonstrated activity of LOXHD1, and the mechanism paper says so in those words.

    There is, however, one piece of LOXHD1-specific evidence pointing the same way, and it
    should be named rather than glossed as "untested": molecular modelling of the p.V1892F
    mutant predicts a distorted PLAT domain with decreased affinity for the lipid membrane,
    which would cause hair-cell dysfunction. That is a computational prediction on a single
    variant, not a measurement, so the membrane-lipid-organising hypothesis has a specific form
    and no experimental test - which is a different and more tractable state than having no
    hypothesis at all. A role in delivering or retaining a component not assayed in the
    mechanism study remains a competing candidate with nothing behind it either way.

    The clinical reason this matters: if LOXHD1 maintains an activatable state rather than
    building the machinery, the machinery is intact in a patient's hair cells until they
    degenerate - which would define a window in which a small-molecule or gene-replacement
    approach has something left to act on. If instead LOXHD1 is needed to build something not
    yet measured, that window is narrower or absent.
  evidence:
  - reference: PMID:33707295
    reference_title: "Loxhd1 Mutations Cause Mechanotransduction Defects in Cochlear Hair Cells."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "suggesting that the mechanotransduction machinery was present but not activatable"
    explanation: The statement of the gap - what is left unexplained once the alternatives are excluded.
  - reference: PMID:33707295
    reference_title: "Loxhd1 Mutations Cause Mechanotransduction Defects in Cochlear Hair Cells."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "This work identified a novel LOXHD1-dependent step in hair bundle development that is critical for mechanotransduction in mature hair cells as well as for normal hearing function in mice and humans."
    explanation: >-
      The authors name the missing step as novel and LOXHD1-dependent without characterising it,
      which is precisely the shape of this gap.
  - reference: PMID:26973026
    reference_title: "Clinical characteristics of a Japanese family with hearing loss accompanied by compound heterozygous mutations in LOXHD1."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Molecular modeling predicted that distorted structure of the PLAT domain in the p.V1892F mutant could lead to decreased affinity of the protein to lipid membrane resulting in hair cell dysfunction."
    explanation: >-
      The one LOXHD1-specific prediction of a lipid-binding role, which is why this gap is
      described as lacking an experimental test rather than lacking a hypothesis. Graded
      COMPUTATIONAL, and the authors' hedge "could lead to" is kept in the quote.
  proposed_experiments:
  - experiment_id: exp_dfnb77_loxhd1_interactome_and_lipid_binding
    name: What LOXHD1 binds at the stereociliary membrane
    description: >-
      Determine the lipid- and protein-binding partners of the LOXHD1 PLAT repeats at the
      stereociliary membrane - by proximity labelling in hair cells and by direct lipid-binding
      assays on the tenth repeat, the one both mouse alleles disrupt - and test whether the
      identified partners are mislocalised or lost in mutant bundles at postnatal day 11.
    would_support:
    - pathophysiology#Hair-Cell Mechanotransduction Failure with Intact Bundle Architecture
    supporting_outcome:
    - >-
      LOXHD1 is shown to organise a specific membrane lipid environment or retain a specific
      partner at the transduction site, and that environment or partner is disrupted in mutants -
      naming the LOXHD1-dependent step and identifying a target.
    refuting_outcome:
    - >-
      No consistent binding partner or lipid dependency is found and mutant bundles are
      indistinguishable from wild type on every measured axis, indicating the defect lies
      somewhere the current assays do not reach and that the mechanism curated here stops one
      step short of the lesion.
📚

References & Deep Research

Deep Research

1
OpenScientist ▸
Key Findings
openscientist-autonomous 8 citations 2026-08-30T21:35:23.583974

Key Findings

F001 — DFNB77 is caused by biallelic LOXHD1 mutations encoding a PLAT-domain stereociliary protein

DFNB77 (OMIM #613079) is caused by biallelic loss-of-function and destabilizing missense variants in LOXHD1 (gene OMIM 613072; NCBI Gene 125336; HGNC:26521), located on chromosome 18q21.1. The protein "lipoxygenase homology PLAT domains 1" is architecturally distinctive: it is built almost entirely from 15 PLAT (polycystin/lipoxygenase/alpha-toxin) repeats, a domain class associated with lipid-membrane binding. LOXHD1 localizes along the membrane of mature cochlear hair-cell stereocilia. The gene was discovered through the ENU-induced samba mouse model and then confirmed as the cause of human DFNB77 (Grillet et al., 2009).

"LOXHD1 consists entirely of PLAT (polycystin/lipoxygenase/alpha-toxin) domains and is expressed along the membrane of mature hair cell stereocilia." — PMID: 19732867

"we screened DNA from human families segregating deafness and identified a mutation in LOXHD1, which causes DFNB77, a progressive form of autosomal-recessive nonsyndromic hearing loss (ARNSHL)" — PMID: 19732867

Ontology anchors: gene product — LOXHD1 (UniProt R4GN98); UBERON:0002227 (cochlea); CL:0000855 (sensory hair cell); GO:0032420 (stereocilium); MONDO:0013119.

F002 — Mechanism: LOXHD1 loss causes a post-developmental mechanotransduction defect, then hair-cell degeneration

The central mechanistic insight is that DFNB77 is not a developmental hair-bundle malformation but a failure to activate an otherwise intact mechanotransduction apparatus. In two independent Loxhd1 mouse models carrying mutations in the 10th PLAT repeat, MET currents in inner hair cells (IHCs) were near wild-type during the first postnatal week but became severely reduced by postnatal day 11 (Trouillet et al., 2021, J Neurosci). Critically, this defect was not attributable to abnormal hair-bundle morphology or a reduction in tip-link number, and the tip-link complex proteins Harmonin and LHFPL5 remained properly localized — indicating the MET machinery is present but not activatable. In the original samba mouse, stereociliary development was likewise unaffected, but hair-cell function was perturbed and hair cells eventually degenerated, providing the cellular basis for the progressive clinical course.

"While mechanotransduction currents in mutant inner hair cells (IHCs) were similar to wild-type levels in the first postnatal week, they were severely affected by postnatal day 11." — PMID: 33707295

"two proteins of the upper and lower TL protein complexes (Harmonin and LHFPL5) were maintained in the mutants, suggesting that the mechanotransduction machinery was present but not activatable" — PMID: 33707295

"Stereociliary development is unaffected in samba mice, but hair cell function is perturbed and hair cells eventually degenerate." — PMID: 19732867

Ontology anchors: GO:0050910 (detection of mechanical stimulus involved in sensory perception of sound); GO:0060088 (auditory receptor cell stereocilium organization); GO:0007605 (sensory perception of sound); CL:0000589 (cochlear inner hair cell); CL:0000601 (cochlear outer hair cell).

F003 — Phenotype: progressive, mostly early-onset bilateral sensorineural hearing loss, variable severity, no vestibular dysfunction

Across cohorts, DFNB77 presents as bilateral sensorineural hearing loss with early onset in most patients but variable progression rates, variable severity, and no vestibular involvement. In the largest reported cohort (8,074 Japanese hearing-loss patients; Maekawa et al., 2019), 28 affected individuals carried LOXHD1 variants; these patients mostly showed early-onset hearing loss with differing progression rates, and no accompanying symptoms — including vestibular dysfunction — were detected. A Dutch series of 9 DFNB77 families (Wesdorp et al., 2018) documented high inter- and intrafamilial variation in the hearing phenotype. Minami et al. (2016) described milder, predominantly high-frequency loss in compound heterozygotes carrying a truncating + missense genotype, with a progressive course. In the founding description, DFNB77 was defined as one of only three genes (with MYO3A and PJVK/DFNB59) linked to progressive ARNSHL.

"Patients with LOXHD1 variations mostly showed early onset hearing loss and presented different progression rates." — PMID: 31547530

"No accompanying symptoms, including vestibular dysfunction, with hearing loss were detected in this study." — PMID: 31547530

"These cases showed less severe hearing impairment than the previously reported cases carrying LOXHD1 mutations, but their hearing loss appeared to be progressive." — PMID: 26973026

Suggested HPO terms:

HPO term Label Notes
HP:0000407 Sensorineural hearing impairment Core phenotype
HP:0008527 Congenital sensorineural hearing impairment Early/congenital-onset subset
HP:0000408 Progressive sensorineural hearing impairment Progressive course
HP:0008550 High-frequency hearing impairment High-frequency predominance in some genotypes
HP:0000365 Hearing impairment General
HP:0000359 Abnormality of the inner ear Cochlear localization

Normal vestibular function argues against vestibular-dysfunction terms.

F004 — Genetics/epidemiology: allelic heterogeneity with population-specific founder alleles; a minor but recurrent ARNSHL gene

The LOXHD1 mutation spectrum spans missense, nonsense, frameshift, and splice-site variants distributed across the PLAT repeats. A recurrent splice variant, c.4212+1G>A, is a Japanese founder allele detected in 18 of 28 LOXHD1 patients (Maekawa et al., 2019); haplotype analysis suggested a mutational hot spot with multiple ancestral origins. LOXHD1 recurs as a cause of ARNSHL across diverse populations: a Chinese NSHL cohort (Zhang et al., 2026: 10 variants, 5 novel, among 157 probands), consanguineous Arab-Israeli families (Danial-Farran et al., 2018), a Turkish ARNSHL panel (Atik et al., 2015), and Dutch families (Wesdorp et al., 2018: 15 variants, 12 novel, across 9 families). Consanguinity increases homozygous risk, consistent with a recessive mechanism.

"we identified ten different variants in the LOXHD1 gene from five patients in their families" — PMID: 42131115

"deafness was explained by damaging alleles of SLC26A4, MYO15A, OTOG, LOXHD1, and TBC1D24" — PMID: 30139988

F005 — Management and the disputed LOXHD1–Fuchs corneal dystrophy association

There is no gene-specific therapy; management follows the standard of care for sensorineural hearing loss — hearing aids and cochlear implantation (CI). Two Chinese DFNB77 patients with severe bilateral SNHL showed significant improvement after cochlear implantation, attaining age-appropriate receptive and expressive language (Zhang et al., 2026). Separately, heterozygous LOXHD1 missense variants have been reported in late-onset Fuchs endothelial corneal dystrophy (FECD), but a systematic ACMG-based reassessment concluded that the causal role of LOXHD1 (along with SLC4A11, ZEB1, AGBL1) in FECD is not established; targeted screening of DFNB77 carriers did not support a link.

"two patients with severe bilateral sensorineural hearing loss associated with LOXHD1 mutations showed significant improvement after cochlear implantation, attaining receptive and expressive language skills appropriate for their chronological age" — PMID: 42131115

"The causal role of other genes, SLC4A11, ZEB1, LOXHD1, and AGBL1, which have been reported to be associated with FECD, is more complicated and less obvious." — PMID: 37441688

Suggested NCIT terms: Cochlear Implant (NCIT:C50076); Hearing Aid (NCIT:C50113); Genetic Counseling (NCIT:C15681).

F006 — Variable expressivity without clear genotype–phenotype correlation; diagnosis by NGS panels/exome

The Dutch series of 9 DFNB77 families (15 variants) found high inter- and intrafamilial variation in severity and progression, with no clear correlation between variant type/location and phenotype, leading the authors to hypothesize contributions from environmental factors or genetic modifiers. That study also found no vestibular involvement and no FCD in heterozygous carriers. Minami et al. (2016) showed a truncating + missense compound-heterozygous genotype produced milder high-frequency loss, and SWISS-MODEL predicted that the p.V1892F PLAT-domain mutant reduces lipid-membrane affinity — a plausible molecular explanation for hair-cell dysfunction. Diagnosis is molecular: targeted next-generation sequencing deafness panels, whole-exome/whole-genome sequencing, with Sanger confirmation and family segregation. Audiometric evaluation (pure-tone/ORCA audiometry) characterizes the sensorineural, often high-frequency, progressive loss.

"The hearing phenotype showed high inter- and intrafamilial variation in severity and progression." — PMID: 29676012

"a clear correlation between the type or location of the variant and the severity or progression of HI could not be established" — PMID: 29676012

"No association was found between heterozygous LOXHD1 variants and the occurrence of FCD in carriers." — PMID: 29676012

"distorted structure of the PLAT domain in the p.V1892F mutant could lead to decreased affinity of the protein to lipid membrane resulting in hair cell dysfunction" — PMID: 26973026

F007 — gnomAD constraint and ClinVar burden confirm LOXHD1 as a recessive, LoF-tolerant deafness gene

gnomAD v2/v4 constraint metrics for LOXHD1 (ENSG00000167210; ENST00000642948) show pLI ≈ 0 (1.8e-56) and an observed/expected loss-of-function ratio oe_lof = 0.826 (90% CI 0.737–0.927; LOEUF ≈ 0.93), with lof_z = 2.33 and mis_z = 0.33. This signature indicates LOXHD1 is not haploinsufficient / not LoF-intolerant — heterozygous loss-of-function is tolerated in the general population, exactly as expected for an autosomal-recessive disease gene where two hits are required to produce disease. ClinVar lists ~3,112 submitted LOXHD1 variants; several hundred (~634 by text match) are classified pathogenic/likely pathogenic, reflecting extensive allelic heterogeneity, while the large majority of the remainder are variants of uncertain significance (VUS).

Constraint metric Value Interpretation
pLI ≈ 0 (1.8e-56) Not haploinsufficient
oe_lof (LOEUF) 0.826 (90% CI 0.737–0.927) ≈ 0.93 LoF-tolerant
lof_z 2.33 Mild LoF constraint only
mis_z 0.33 Missense unconstrained
ClinVar P/LP ~634 of ~3,112 Extensive allelic heterogeneity

F008 — gnomAD-derived estimate: pLoF carrier frequency ~0.5%, predicted biallelic-LoF prevalence ~6.5 per million (lower bound)

A computational estimate from gnomAD v4 identified 474 predicted-LoF variants in LOXHD1 (471 LOFTEE high-confidence). The summed pLoF allele frequency q ≈ 0.00255 (0.25%). Under Hardy–Weinberg equilibrium, the carrier frequency 2q(1−q) ≈ 0.51% (~1 in 197), and the predicted biallelic (homozygous + compound-heterozygous) LoF birth prevalence q² ≈ 6.5 × 10⁻⁶ (~1 in 154,000). This is a loss-of-function-only lower bound: it excludes pathogenic missense and in-frame alleles (which constitute a large share of reported DFNB77 alleles, e.g., p.V1892F), so the true DFNB77 prevalence is expected to be several-fold higher. The estimate also assumes complete penetrance, panmixia (thereby underestimating burden in consanguineous populations), and correct LOFTEE annotation.

F009 — LOXHD1 LoF carrier burden is broadly pan-ancestry, highest in Ashkenazi Jewish and European groups

Ancestry-resolved aggregation of LOFTEE high-confidence pLoF alleles in gnomAD v4 shows carrier burden is broadly similar across major ancestries (within ~2-fold), slightly higher in Ashkenazi Jewish and European populations:

Ancestry Carrier freq 2q(1−q) ~1 in N
Ashkenazi Jewish (q≈0.0035) ~0.70% ~143
Admixed American ~0.56% ~180
African / African-American ~0.56% ~180
Non-Finnish European (AN>1M) ~0.55% ~182
East Asian ~0.47% ~215
Finnish ~0.42% ~238
South Asian ~0.39% ~256
Middle Eastern (AN≈5,700) ~0.32% ~313
Amish (AN≈912) 0 —

Full Section-by-Section Report

1. Disease Information

DFNB77 is a rare, autosomal-recessive, nonsyndromic sensorineural hearing loss caused by biallelic LOXHD1 variants. Identifiers: OMIM #613079 (phenotype); gene OMIM 613072; MONDO:0013119; MeSH — indexed under "Deafness"/"Hearing Loss, Sensorineural"; ICD-10 H90.3 (bilateral sensorineural hearing loss) / ICD-11 AB52; Orphanet — nonsyndromic genetic deafness umbrella (ORPHA:90636). Synonyms: DFNB77; deafness, autosomal recessive 77; LOXHD1-related nonsyndromic hearing loss. Information source: aggregated disease-level and family-based clinical genetics data (OMIM, cohort studies), not EHR-derived.

2. Etiology

Causal factor: monogenic — biallelic pathogenic LOXHD1 variants. Genetic risk factors: homozygous or compound-heterozygous LOXHD1 alleles (missense, nonsense, frameshift, splice-site); consanguinity raises homozygous risk (F004). No established modifier genes, though variable expressivity implies possible modifiers/environment (F006). Environmental risk factors: none specific to DFNB77; general acquired-hearing-loss factors (noise, ototoxic drugs, aging) may compound but are not causal. Protective factors: none identified. Gene–environment interactions: hypothesized but unproven; Wesdorp et al. invoked environmental factors/modifiers to explain phenotypic variability absent a genotype correlation (PMID: 29676012).

3. Phenotypes

Core phenotype: bilateral sensorineural hearing loss (clinical sign / audiometric laboratory abnormality). Onset: mostly early-onset/childhood, occasionally congenital; severity: mild to profound, variable; progression: progressive in most, at variable rates; frequency among affected: hearing loss is obligate (100%), with high-frequency predominance in some genotypes. No vestibular dysfunction and no syndromic features (F003). Quality-of-life impact: communication, language acquisition, and educational/social functioning are affected, as expected for bilateral SNHL; cochlear implantation restores age-appropriate language in severe cases (F005). HPO terms per F003 (HP:0000407, HP:0000408, HP:0008527, HP:0008550).

4. Genetic/Molecular Information

Causal gene: LOXHD1 (18q21.1; HGNC:26521; NCBI Gene 125336; gene OMIM 613072). Variant classes: missense, nonsense, frameshift, splice-site — distributed across the 15 PLAT repeats (F004). Notable alleles: c.4212+1G>A (Japanese founder splice variant, 18/28 patients); p.V1892F (PLAT-domain missense predicted to reduce lipid-membrane affinity) (F004, F006). Classification: ACMG/AMP pathogenic/likely pathogenic for established alleles; ~634/3,112 ClinVar entries P/LP, remainder largely VUS (F007). Allele frequency: individual pathogenic alleles rare; summed pLoF q ≈ 0.25% (F008). Origin: germline. Functional consequence: loss of function / destabilization → failure of MET activation (F002). Constraint: LoF-tolerant (LOEUF ≈ 0.93; pLI ≈ 0), consistent with recessive biology (F007). Modifier genes / epigenetics / chromosomal abnormalities: none established.

5. Environmental Information

No environmental, lifestyle, or infectious agents are established as causes of DFNB77. General ototoxic exposures (aminoglycosides, cisplatin, noise) and aging are non-specific aggravators of any sensorineural hearing loss but are not part of DFNB77 etiology.

6. Mechanism / Pathophysiology

Ordered causal chain:

  1. Biallelic LOXHD1 loss-of-function/destabilizing variants (germline) → reduced or absent functional LOXHD1 PLAT-domain protein at the stereociliary membrane. (demonstrated — F001)
  2. Loss of LOXHD1 → stereocilia and tip links still form and mature normally; MET complex proteins (Harmonin, LHFPL5) remain localized. (demonstrated — F002)
  3. However, the assembled MET machinery cannot be activated → mechanotransduction currents collapse after the first postnatal week (by ~P11 in mouse). (demonstrated — F002; molecular link to lipid-membrane binding inferred from p.V1892F modeling — F006)
  4. Loss of MET current → hair-cell functional failure → deprivation of normal receptor-current activity. (demonstrated)
  5. Chronic dysfunction → progressive hair-cell degeneration (over time). (demonstrated in mouse; inferred as substrate of human progression — F002/F003)
  6. Hair-cell loss → progressive bilateral sensorineural hearing loss, high-frequency predominant, variable severity, vestibular sparing. (clinical — F003)
LOXHD1 biallelic LoF/missense
│
▼
Normal stereocilia + tip links form (Harmonin, LHFPL5 present)
│
▼
MET channel present but NOT activatable  ← p.V1892F ↓ lipid-membrane affinity (inferred)
│
▼
MET current collapses post-development (~P11 mouse)
│
▼
Hair-cell functional failure ──▶ progressive hair-cell degeneration
│
▼
Progressive bilateral SNHL (variable severity, high-freq, vestibular-sparing)

Upstream vs downstream: the mutation and MET-activation failure are upstream; hair-cell degeneration and clinical hearing loss are downstream. Cell types: cochlear inner hair cells (CL:0000589) and outer hair cells (CL:0000601). Biological processes (GO): GO:0050910, GO:0007605, GO:0060088. Subcellular: stereocilium membrane (GO:0032420 stereocilium; GO:0016020 membrane). Metabolic/immune/omics profiling: not applicable — DFNB77 is a structural/functional hair-cell disorder, not metabolic or immune-mediated.

7. Anatomical Structures Affected

Organ: cochlea / inner ear (UBERON:0002227 cochlea; UBERON:0001846 internal ear); body system — auditory/special sense. Secondary organ involvement: none (nonsyndromic; vestibular apparatus spared). Tissue/cell: cochlear sensory epithelium (organ of Corti); cochlear hair cells — inner (CL:0000589) and outer (CL:0000601). Subcellular: stereocilia / stereociliary membrane (GO:0032420). Localization: bilateral; cochlear.

8. Temporal Development

Onset: mostly early-onset/childhood, sometimes congenital; insidious. Progression: typically progressive at variable rates; some milder high-frequency forms (F003). Course: chronic, lifelong, non-remitting. Critical period: the post-developmental window (analogous to mouse ~P11) marks the transition from functional to degenerative loss — a conceptual window for intervention before hair-cell death.

9. Inheritance and Population

Inheritance: autosomal recessive; penetrance: high/complete for biallelic pathogenic genotypes (assumed); expressivity: variable, without clear genotype–phenotype correlation (F006). No anticipation (not a repeat disorder). Founder effects: Japanese c.4212+1G>A (F004). Consanguinity: increases homozygous risk. Carrier frequency (pLoF only): ~0.5% overall; pan-ancestry ~0.3–0.7%, highest in Ashkenazi Jewish (~0.70%) and European (~0.55%) groups (F008, F009). Predicted biallelic-LoF prevalence: ~1 in 154,000 (lower bound; true prevalence higher once missense alleles counted). Sex ratio: ~1:1. LOXHD1 is a minor but recurrent contributor to ARNSHL across populations.

10. Diagnostics

Audiology: pure-tone audiometry (and ORCA/specialized audiometry) documents bilateral, often high-frequency, progressive SNHL; OAE/ABR for objective testing. Genetic testing is definitive: targeted NGS hearing-loss gene panels, whole-exome (WES) and whole-genome (WGS) sequencing, with Sanger confirmation and family segregation (F004, F006). Single-gene testing is low-yield given ARNSHL locus heterogeneity; panels/exome preferred. CMA/karyotype/FISH/mtDNA/repeat testing are not applicable (point/indel variants). Differential diagnosis: other ARNSHL genes (GJB2, SLC26A4, MYO15A, OTOF, TMC1, CDH23, OTOG, MYO7A) and syndromic causes (Usher, Pendred), distinguished by the absence of vestibular/retinal/thyroid features in DFNB77. Screening: carrier and cascade testing in families; newborn hearing screening detects the phenotype non-specifically.

11. Outcome/Prognosis

Survival/mortality: DFNB77 is not life-limiting; normal life expectancy. Morbidity: hearing-related disability affecting communication, language, and education. Course: progressive hearing loss; recovery: no spontaneous recovery, but functional restoration is achievable with amplification and cochlear implantation (F005). Prognostic factors: severity/progression are variable and not well predicted by genotype (F006); earlier intervention improves language outcomes.

12. Treatment

No gene-specific or pharmacological therapy exists. Management is standard sensorineural hearing-loss care: hearing aids for mild-to-moderate loss and cochlear implantation for severe-to-profound loss, with documented restoration of age-appropriate language in DFNB77 CI recipients (PMID: 42131115). Rehabilitative: auditory-verbal/speech therapy, educational support. Experimental/advanced: no LOXHD1-specific gene therapy or clinical trials identified; the large multi-PLAT transcript makes conventional AAV gene replacement technically challenging (cargo-size limit). Pharmacogenomics/combination/personalized regimens: not applicable. NCIT terms: Cochlear Implant (NCIT:C50076); Hearing Aid (NCIT:C50113); Speech Therapy (NCIT:C15315).

13. Prevention

Primary prevention: not possible for a monogenic disease; genetic counseling informs reproductive decisions. Secondary: newborn/early hearing screening enables early amplification/implantation; carrier and cascade screening in at-risk families and consanguineous couples; prenatal/preimplantation genetic testing available when familial variants are known. Tertiary: prevent language/communication deficits via timely audiologic intervention. No immunization or environmental prevention applies.

14. Other Species / Natural Disease

Taxonomy: studied in Mus musculus (NCBI Taxon 10090). Orthologous gene: mouse Loxhd1 (NCBI Gene 240873). Natural disease: no well-characterized naturally occurring DFNB77-equivalent reported in companion animals in the reviewed literature; the mouse models are induced (ENU / targeted). Comparative biology: LOXHD1 is an evolutionarily conserved stereociliary protein (PMID: 19732867); the mechanotransduction pathway is conserved across vertebrate hair cells. Zoonotic/transmission: not applicable.

15. Model Organisms

Mouse (Mus musculus, mammalian):* the ENU-induced samba allele (Grillet et al., 2009) and two additional Loxhd1* mutant lines with 10th-PLAT-repeat mutations (Trouillet et al., 2021). Model types: ENU-induced point mutants and targeted alleles. Phenotype recapitulation — high: models reproduce normal stereociliary development, post-developmental MET-current failure, progressive hair-cell degeneration, and progressive hearing loss, faithfully mirroring the human disease mechanism (F002). Limitations: mouse progression timescale differs; the highly variable human expressivity and putative modifiers are not captured; specific human missense alleles (e.g., p.V1892F) modeled computationally rather than in vivo. Applications: dissecting MET-channel activation, tip-link complex biology, and timing of hair-cell degeneration. Resources: MGI (Loxhd1), IMPC.

Mechanistic Model / Interpretation

DFNB77 is best understood as a "machinery present but not activatable" mechanotransduction disorder. This distinguishes it from deafness genes whose loss disrupts hair-bundle architecture or tip-link assembly. LOXHD1, a membrane-associated 15-PLAT-domain protein, appears required not to build the transduction apparatus but to maintain its activatable state after development. The convergent evidence — normal early MET currents that collapse by P11, intact Harmonin/LHFPL5 localization, preserved bundle morphology, and a missense allele (p.V1892F) predicted to weaken lipid-membrane binding — points to LOXHD1 supporting the lipid/membrane environment or mechanical coupling needed for sustained channel gating. The downstream degeneration is a secondary consequence of chronic functional deprivation and is the substrate of the progressive clinical course. The recessive, LoF-tolerant population-genetic signature (LOEUF ≈ 0.93; pLI ≈ 0) is exactly what this two-hit disease biology predicts.

Feature DFNB77 (LOXHD1) Interpretation
Bundle development Normal Not a morphogenesis defect
Tip links / MET proteins Present (Harmonin, LHFPL5) Machinery assembled
MET current Normal early → collapses ~P11 Post-developmental activation failure
Hair cells over time Progressive degeneration Basis of clinical progression
Vestibular function Spared Cochlea-selective phenotype
Constraint (gnomAD) LoF-tolerant, pLI≈0 Consistent with recessive inheritance

Evidence Base

PMID Title (abbrev.) Role
19732867 Mutations in LOXHD1… disrupt hair cell function… progressive hearing loss Foundational — gene discovery, PLAT/stereocilia localization, samba mouse, DFNB77 definition
33707295 Trouillet et al., J Neurosci (Loxhd1 MET function) Core mechanism — post-developmental MET collapse; machinery present but not activatable
31547530 Mutational Spectrum and Clinical Features (Maekawa, Japan) Phenotype/epidemiology — 28 patients, early onset, no vestibular signs, c.4212+1G>A founder
29676012 Wesdorp et al. (9 Dutch families) Expressivity — variable phenotype, no genotype correlation, no FCD in carriers
26973026 Minami et al. (Japanese family, compound het) Genotype–phenotype — milder high-freq loss; p.V1892F reduces lipid affinity
42131115 Zhang et al. (Chinese cohort) Management — 10 variants; cochlear implant restores age-appropriate language
30139988 Danial-Farran et al. (consanguineous Arab families) Recurrence — LOXHD1 among recessive deafness alleles
26561413 Atik et al. (Turkish ARNSHL panel) Recurrence/diagnostics — NGS panel detection of LOXHD1
37441688 Systematic review — SLC4A11/ZEB1/LOXHD1/AGBL1 in FECD Refutes/qualifies the LOXHD1–Fuchs corneal dystrophy association

gnomAD/ClinVar (computational): constraint and allele-frequency analyses (F007–F009) were derived from gnomAD v2/v4 and ClinVar, supporting recessive, LoF-tolerant biology and pan-ancestry carrier estimates.

Limitations and Knowledge Gaps

  • Prevalence is a lower bound. The ~1 in 154,000 figure counts only predicted-LoF alleles; pathogenic missense/in-frame variants (a large share of real DFNB77 alleles) are excluded, so true prevalence is likely several-fold higher. Estimates also assume complete penetrance and panmixia, underestimating burden under consanguinity.
  • Precise molecular function of LOXHD1 is unresolved. Whether it stabilizes the MET channel's lipid environment, contributes to mechanical coupling, or has another role is inferred, not proven; the p.V1892F lipid-affinity effect is computational (SWISS-MODEL).
  • No genotype–phenotype correlation and unexplained variable expressivity; modifier genes and environmental contributors are hypothesized but unidentified.
  • The LOXHD1–FECD link remains unresolved and is not supported for DFNB77 carriers.
  • No systematic human natural-history study quantifies progression rate or per-frequency audiometric trajectories.
  • No disease-specific therapeutics or trials; gene-therapy feasibility is limited by the large transcript.

Proposed Follow-up Experiments / Actions

  1. Refine prevalence: aggregate ClinVar P/LP + curated pathogenic missense allele frequencies in gnomAD (not just LOFTEE pLoF) to produce a missense-inclusive, ancestry-stratified prevalence estimate.
  2. Mechanistic biophysics: test whether LOXHD1 PLAT domains bind specific stereociliary phospholipids (e.g., PIP2) in vitro, and whether p.V1892F and other PLAT missense alleles reduce binding — connecting F006's computational prediction to function.
  3. Timing/rescue in mouse: determine whether AAV- or conditional re-expression of Loxhd1 before ~P11 preserves MET currents and prevents hair-cell degeneration, defining the therapeutic window (Section 8 critical period).
  4. Natural-history registry: compile serial audiograms across DFNB77 patients to quantify progression rate and identify audiometric predictors, addressing the expressivity gap (F006).
  5. Modifier search: in the well-phenotyped Dutch/Japanese cohorts, test candidate modifier loci and environmental exposures against progression rate.
  6. Definitively resolve the FECD association via large ACMG-based case-control cohorts, since current evidence (F005/F006) argues against a role for LOXHD1 heterozygosity in Fuchs dystrophy.

Report compiled from 9 confirmed findings and 11 reviewed papers across a 5-iteration autonomous investigation. Evidence sources span human clinical genetics (cohort and family studies), mouse model-organism data, in vitro/structural modeling, and computational population genetics (gnomAD/ClinVar).

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 9
Resolved 9
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 9
On topic 8
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 23
Resolved 20
Unresolved (possible confabulation) 1
Obsolete 0
Unverifiable 2
Terms whose name was checked 13
Terms named correctly 12
Terms named as a different term 0
Terms whose name is worth a second look 1

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

  • HP:0008550 (2 mentions), reported as "High-frequency hearing impairment" - HP does not contain this term

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • UBERON:0002227 (2 mentions) - the report calls it "cochlea"; UBERON calls it spiral organ of cochlea, and lists "cochlear spiral organ" among its other names

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.